Methods: The total number of accesses to the emergency department of the Children's Hospital G. Cristina in Palermo was retrospectively analyzed in the two-year period [2009] [2010] and in the two-year period 2017-2018 in order to examine the differences over a period of 10 years. The percentage of accesses for headache and the number of specialistic assessments and of imaging procedures (computed tomography) have been analyzed in the two periods examined. Results: The total accesses to the emergency department have decreased from 55,616 to 50,096 (-10%) between the two-year periods considered while the number of accesses for headache has increased by around 63.56% (p<0.0001). The highest increase occurred in the age groups of 7-13 and 14-17 (respectively 69.23% and 52.12%). The increase is mainly due to the entry of probable primary headaches or not classifiable headaches (about 67% of the total increase), especially for the age group 7-13 and for the group 14-17. At the same time the number of child neuropsychiatric assessments and the number of computed tomography have remarkably increased. Conclusions: The significant increase of accesses for pediatric headaches is probably due to the limited efficacy of the Italian and international guidelines and of the educational strategies, underlying the existing connection difficulties between the primary care network and hospitals. It is also important to reflect on the use of red flags because many of them probably have poor sensitivity and specificity. This results in an avoidable overcrowding of the emergency department for useless accesses, in an increase of unnecessary assessments and procedures and, in the end, in an increase of health costs.
Migraine and insomnia: observational study at the headache ambulatory Cassino/Sora O. Di Marco
, S. Di Mauro
Background: Alice in Wonderland Syndrome (AIWS) is a complex disorder of sensory misperception, mostly involving visual and somatosensory integration. AIWS has been associated with several medical conditions, although migraine is the most common cause in adults. However, the reason behind this association is not yet clear. As the first step to better defining this association, we performed an epidemiological survey with a longitudinal follow-up to understand epidemiological and clinical overlap between the two conditions. Material and methods: Over the course of 1 year, all the first-visit outpatients of our Tertiary Headache Centre were consecutively screened for AIWS symptoms by means of a custom-made questionnaire. Patients answering positively to the questionnaire were double-checked with medical interview by headache specialist physicians trained in AIWS. Medical investigations and migraine acute and preventive therapy were chosen according to migraine history (regardless AIWS). Headache patients who also had AIWS were clinically followed up for other 12 months. Results: During 1 year, 31 (18%) patients were confirmed to have experienced at least a lifetime AIWS episode. All AIWS patients were diagnosed with migraine with aura (according to ICHD-3) all but 4 had an episodic form. Mean age was 40.9 years and the female/male proportion was 26/5; 23 (74%) patients presented only visual disturbances as AIWS symptoms, while eight (26%) had visual-somatosensory AIWS symptoms. No patient in our sample had only somatosensory AIWS symptoms. In all but 2 patients AIWS symptoms occurred only during migraine with aura attacks. During the follow-up, 9 patients dropped out. In 16 out of the 22 left, we prescribed preventive treatments for migraine (e.g antiepileptics, β-blockers and tricyclic antidepressants): half of these patients reported no new episode of AIWS, while the others referred at least a decrease in frequency. In the 6 patients in whom we did not introduce preventive therapy due to a low frequency of attacks, 4 were still experiencing AIWS symptoms. Conclusions: In migraine, AIWS prevalence seems to be higher than expected. Moreover, AIWS is strongly associated to migraine with aura, mostly during the migraine with aura attack itself, suggesting that AIWS seems to depend somehow on aura mechanisms. For this reason, it is not surprising that, contrary to literature data showing the existence of AIWS symptoms involving only somatosensory functions, migraine patients had also disturbances of visual cortices, where cortical spreading depression principally occurs. Due to this association, it seems sound that preventive therapy for migraine also reduced AIWS symptoms.
Qualitative and quantitative relationships between right-to-left shunt and white matter brain hyperintensities in patients with migraine the two conditions and the modifying effect of aura, age, and migraine frequency are unclear. We aimed to assess the qualitative and quantitative relationships between RLS and WMHs in a group of subjects with episodic (EM) or chronic migraine (CM), with (MA) or without aura (MO). Methods: We included consecutive patients with migraine referring to our tertiary Headache Center. For each patient, we recorded sex, age, and vascular risk factors, together with migraine characteristics including frequency, aura, and age at onset. Each patient underwent a 3 Tesla brain MRI scan and a transcranial Doppler ultrasonogram to detect RLS, quantified as mild, moderate, or severe. WMH burden was quantified by lesion counting and by the Fazekas score. We performed the chi squared or Spearman's correlation tests. Results: We included 77 subjects, 85.7% female, with a mean age of 43.4 ±9.3 years and a mean age at migraine onset of 20.7±8.8 years. Thirty-five (45.5%) patients had RLS, 23 (65.7%) in basal conditions and 12 (23.3%) only after the Valsalva maneuver, while 27 (35.1%) had WMHs. We found no association between the presence of RLS and that of WMHs (P=0.657); this result was similar within patients with EM and CM, MA and MO. We found a negative correlation between age at migraine onset and basal RLS severity in patients with EM (Rho= -0.540; P=0.031) and in those with MA (Rho= -0.714, P=0.019) but not in those with CM or MO. We also found a positive correlation between age and the number of WMHs (Rho=0.380; P=0.001) or the Fazekas' score (Rho=0.297; P=0.009), while no quantitative correlation was found between RLS severity and the number of WMHs or the Fazekas' score. The positive correlation between age and the number of WMHs regarded CM (Rho=0.380, P=0.038), EM (Rho=0.328, P=0.039), MA (Rho=0.548, P=0.019), and MO (Rho=0.360, P=0.009). Migraine frequency was positively correlated with RLS after the Valsalva maneuver only in patients with MO (Rho=0.448; P=0.032) . Conclusions: According to our data, RLS and WMHs, both highly prevalent in patients with migraine but are not associated. Patients with higher RLS severity had an earlier onset of EM or MA and an increased frequency of MO, while WMH burden increased with age.
Aeroplane travel trigeminal neuralgia. Description of a case F. Granella, E. Tsantes, V. Bazzurri A. Fiore, E. Curti Unità di Neuroscienze, Dipartimento di Medicina e Chirurgia, Università di Parma, Italy; e-mail: franco.granella@unipr.it Background: Headache attributed to aeroplane travel (HAAT) is a recently identified headache occurring during and caused by aeroplane travel. It is characterized by severe, unilateral, orbitofrontal pain, of jabbing or stabbing quality, occurring predominantly during the descent phase of a plane and promptly remitting after landing. It is generally believed to be caused by an imbalance between intrasinus and external air pressures. Here we describe a HAAT with clinical features indistinguishable from those of idiopathic trigeminal neuralgia (TN). Case report: During the descent phase of a flight a 18-year-old female complained of a very severe (10 on a 1-10 scale) tightening pain in the right zygomatic and maxillary regions. No accompanying symptoms were noted. The pressing pain lasted about 10 minutes, ceasing after landing, but recurrent brief electric shock-like pains in the same region started immediately afterwards. Pain lasted 2-3 minutes and was extremely severe, recurring every few minutes. No neurovegetative symptoms were present. The attacks were always spontaneous and could not be precipitated by innocuous stimuli. A low-grade, pressing pain persisted in between pain paroxysms. Naproxen sodium 550 mg and paracetamol 1,000 mg were only modestly effective in reducing, but not abolishing, painful paroxysms for a couple of hours. After 2 days the attacks resolved spontaneously. Neurological examination was normal as well as 3-T brain MRI and paranasal sinus CT. A second episode with similar characteristics occurred during another flight, beginning just before landing and continuing for three days afterwards.
Conclusions: HAAT typically begins during the descent phase of a flight and lasts less than 30 minutes. In few cases, headache persisted for days or even for two weeks, but it was described as a continuous mild pain, pressing in nature. To our knowledge, this is the first case of HAAT Background: Chronic Daily Headache (CDH) is defined as headache occurring at least 4 hours per day, 15 days or more a month, for longer than 3 months (ICHD III). New daily-persistent headache (NDPH), a variety of CDH, is daily unremitting headache essentially since onset, in patients without significant prior history of headache. There are few studies about CDH in the pediatric age; the reported prevalence ranged from 0.9% to 7.8%, and it is higher in girls than boys. The pathogenesis of CDH in children is multifactorial and involves genetic, familial, cultural and environmental factors. The aim of this study was to describe epidemiological features of a pediatric population with CDH. Methods: All the patients referred as first visit to the Pediatric Headache Centre (PHC) of the Regina Margherita Children's Hospital of Turin, Italy, between January 2015 and October 2017 were retrospectively reviewed. We screened the medical record databases of our PHC. Descriptive analysis is provided. Results: Seven hundred and nineteen patients had their first visit in our PHC during the study period (median age: 11 years, range 2-18; females: 51%). Overall, the diagnoses were migraine (55.0%), not classified (13.6%), mixed headache (13.5%), tension-type headache (9.1%) and CHD (8.2%). The mean age of children with CDH was 11 years (range 5-18); 38 were females (16 of them had already had menarche) and 21 males. The subtypes of CDH were: NPDH (56.0%), chronic migraine (16.9%), mixed forms (10.0%), chronic tension-type headache (8.5%), not classified (5.0%). Most children (91.0%) with CDH had familiar history for headache; 44.0% had sleep disorders. Almost all patients with CDH needed prophylactic treatment: 20% with benefit, 10% not improved, 70% were missed at follow-up; 44% were referred to a neuropsychiatrician and 69.2% of them continued this follow-up. Conclusions: CDH is not rare in the pediatric age; in our population, its prevalence was similar to previous reports and the most frequent subtypes was NPDH. The treatment required multimodal approach including both pharmacological and non-pharmacological therapies and collaboration with neuropsychiatric specialists.
Epidemiology, clinical features and family history for major cardiovascular events in children with migraine: a 12-year retrospective study 
Background:
We report a study that analyze epidemiology, clinical features and family history for cardiovascular events in children with migraine. Methods: A retrospective study was performed over 12 years. The hospital record databases were screened for migraine with (MA) or without aura (MO), based on ICHD-II (until 2013) and III beta criteria. Descriptive and multivariate analysis is provided; significance at p<0.05. Results: Migraine was diagnosed in 851 children (25.3% MA, 74.7% MO) , mainly between 9 and 14 years. Children with MA were significantly older than those with MO (mean (SD) age: 12.0 (2.3) and 9.8 (2.4) years, respectively) (p<0.001). After stratification into 5 age-groups, we observed that females with MA prevailed significantly in the group 12-14 years (p=0.003), while males with MO prevailed significantly in the group 9-11 years (p=0.005). In both groups, the attacks were usually severe, infrequent (≤3/month), and lasting <2 hours; nausea/vomiting, photophobia, and phonophobia were more frequent in MO. Visual auras were the most common occurrence (87.4%). Family history of headache was reported in 91.5% children with MA and 95.2% with MO. Family history for cerebral ischemic events <50 years was significantly more reported by children with MA (12.9%) than with MO (5.0%) (p<0.001) and the control group of healthy children (6.3%) (p=0.012). The prevalence of family history for deep venous thrombosis (DVT) was significantly higher in children with MA (4.5%) than in those with MO (1.8%) (p=0.038). Comparing family history for stroke and transitory ischemic attack, we observed moderately increased risk in MA vs MO (Odds Ratio: 2.8; confidence interval: 1.62-4.8) and vs control group (Odds Ratio: 3.3; confidence interval: 1.6-6.5). Moreover, comparing family history for DVT we observed moderately increased risk for MA (Odds Ratio: 2.5 confidence interval: 1.02-6.13). Conclusions: We describe the characteristics of pediatric migraine, showing a likely significant loss of diagnoses using ICHD-III beta criteria, due to duration limits. Children with MA are older and more frequently female than those with MO. Anyway, MO occurs more commonly and shows more frequent attacks and a higher prevalence of associated symptoms. Migraine may be a risk factor to develop ischemic stroke in young adults. In our study, we observed that family history for cerebral ischemic events ≤50 years leads to significantly increased risk of developing MA. Further studies are needed to explore the mechanism underneath this association.
Gender differences in the clinical features of cluster headache: results from a single-center study Background: Cluster headache (CH) is the most severe primary headache disorder. The disease has a prevalence of around 0.1% of the general population, and its onset can occur at almost any age. CH was historically considered to have a male preponderance, with a high male-to-female ratio. However, recent studies observed that there is a downward trend in male preponderance. Clinical features are generally reported to be similar in both genders. The aim of our study was to review our large single-center series of CH patients that were followed in a period of about 10 years in our Neurology Department, in order to analyse demographic, epidemiological and clinical features of the disease. Methods: One hundred and ninety-seven patients with cluster headache (155 males and 42 females, mean age± SD: 43.8±12.1 years) were recruited for the study at the Department of Neuroscience, University of Torino, Italy. CH diagnosis was performed according to the ICHD-III criteria. Demographic factors, clinical characteristics, comorbid medical conditions, family history, triggers, and smoking history were collected according to a standardized questionnaire. Results: In our sample, the male-to-female ratio was 3.7. No difference in smoking history was found between females and males. Age at onset of CH did not differ from females and males (27.4±12.05 yrs vs 25.0±9.55 yrs, p=0.19). Woman cluster headache sufferers had a lower number of attacks a day in respect to men (p=0.03), and less nocturnal attacks (p=0.04). Circadian periodicity for CH is less present in females in respect to males (p=0.01). Interestingly, women were significantly more likely to experience during a CH attack concomitant symptoms not included in the diagnostic criteria for CH, as nausea (p=0.001) and photo/phonophobia (p=0.02). For acute treatment, no significant gender differences were observed. Among the comorbid conditions, female CH sufferers were significantly more likely to experience depression and insomnia than males (p=0.02 and p=0.03, respectively). Conclusions: This study confirms the presence of gender-related differences in the clinical characteristics of CH. Notably, women were significantly more likely to experience also nausea and photo/phonophobia during a CH attack. Thence, CH could be under and misdiagnosed in women also for the presence of concomitant symptoms not included in the diagnostic criteria for CH, that could resemble migraine. Neurobiology mechanisms involved in these gender-related differences of CH characteristics need further studies.
Occupational risk factors and impact on job performance of primary headache among staff of a Roman Hospital: a case-control study Background: Primary headaches account for 90% of all the forms of headache. The disease is characterized by high occurrence in the working-age population and by significant impact in countries with high economic and social development. In an occupational setting, several physical, psycho-social or organizational circumstances are known to cause the onset of attacks in workers who already suffer from primary headache. To date, epidemiological data on the prevalence of headache in hospital workers in Rome are lacking. We therefore performed a study to assess the prevalence of primary headache, and the occupational factors associated with a headache attack among medical and paramedical staff of the Policlinico Tor Vergata in Rome. In addition, we evaluated the impact of loss of performance due to absenteeism and presenteeism caused by headache disorders. Methods: Four hundred and seven patients were consecutively interviewed from the Headache Center and Department of Occupational Medicine of the Policlinico Tor Vergata. Participants filled out a structured questionnaire to gather demographic and socioeconomic data, headache characteristics over the previous year, and occupation-related factors. The demographic and headache profile sections of the questionnaire were the same items as used in other epidemiological studies and were validated for headache assessment and diagnosis in the general population. Data were processed and analysed using MATLAB software. Multivariate logistic regression was applied to identify odd ratios with 95% confidence intervals for different types of headache, according to social-demographic characteristics. Statistical significance was set at p < 0.05. Results: The form of primary headache with higher prevalence was represented by migraine without aura (51.5% of all headache workers) followed by tension-type headache (42.5%) and by migraine with aura (6%). A positive family history was found in 60% of patients and many of them had a disease duration longer than 5 years. Multivariate analysis showed that female sex, smoking, prolonged use of display screen and acoustic discomfort were a statistically significant risk factor for migraine; job satisfaction seemed to have a protective role. The probability of having a severe impact of the headache on daily life was associated with the increase of frequency attack and pain intensity, correlating with reduced work performance and more absenteeism. Conclusions: Primary headache is very common but generally neglected disorder. It is a remarkably disabling condition and occupational factors may play an important role. Awareness and avoidance of trigger factors can not only decrease the frequency of headache but also reduce the possibility of chronic headache and medication overuse, guaranteeing the working health of workers and thus improve their output.
Allopregnanolone serum levels in female migraineurs Background: Migraine and epilepsy are similar brain disorders in many aspects and for both, a neuronal hyperexcitability has been hypothesized. Cyclic changes in ovarian hormones are involved in exacerbating both migraine and epilepsy during perimenstrual period, leading to menstrually-related migraine and catamenial epilepsy, respectively. Ovarian hormones and derived neurosteroids can regulate important functions in neurons and glial cells in the brain; in particular, progesterone reduces seizure susceptibility partly through its conversion to allopregnanolone, a potent positive allosteric modulator of the GABA-A receptor [1] . In spite of their neuroprotective potential [2] , the role of neurosteroids in migraine has not been thoroughly investigated. Therefore, we determined serum levels of testosterone, progesterone and allopregnanolone in three groups: women suffering from menstrually-related migraine (n=30), post-menopausal women suffering from migraine without aura (n=30) and non-headache control females (n=20). Methods: The enrolled migraineurs were patients afferent to the Headache Centre of Modena University Hospital; the control females were friends or relatives of the above patients. All women gave their written consent and the Ethical Committee of the Province of Modena approved the study. The fasting blood specimens were processed and then analyzed by HPLC-ESI-MS/MS. Results: Testosterone and progesterone levels were significantly higher in both non-headache control females and women suffering from menstrually-related migraine compared to post-menopausal women suffering from migraine without aura (P<0.005, t-test). Conversely, serum allopregnanolone levels were significantly lower in both women suffering from menstrually-related migraine (0.051 ng/mL; SD: 0.018) and postmenopausal women suffering from migraine without aura (0.025 ng/mL; SD: 0.013), compared to non-headache control females (0.078 ng/mL; SD 0.036, P<0.005, t-test). Conclusions: Women suffering from migraine presented low serum levels of allopregnanolone, a neurosteroid that modulates GABAergic inhibition. Consequently, the reduced GABAergic inhibition could inadequately protect women suffering from migraine against inflammatory and algogenic stimuli. In particular, it could contribute to the severity and poor response to treatments of migraine attacks. According to our preliminary results, a raise in the GABAergic transmission achieved by drugs increasing the biosynthetic pathway of inhibitory neurosteroids or the use of synthetic analogs could represent a possible novel therapeutic strategy for migraine management. Background: Hemiplegic migraine (HM) is a form of migraine with aura, in which attacks are associated with both typical aura and fully reversible motor weakness. In the sporadic hemiplegic migraine (SHM) no first-or second-degree relative is affected by migraine with motor aura. HM is genetically heterogeneous. Mutations in three ion transportation genes (i.e. CACNA1A, ATP1A2, SCN1A) can all cause the familial phenotype, but more, so far unknown, genes are implicated. Among putative genes for HM there is PRRT2 (i.e. proline rich transmembrane domain protein 2) that can also be involved with paroxysmal movement disorders. Nearly 200 patients affected by SHM have been described, although worldwide epidemiological studies on HM have never been performed. The therapeutic management of HM is empirical, relying on the general principles of treatment of migraine and on evidence mainly coming from reports of patients affected. Case report: A 21-years-old woman was evaluated for attacks that consisted of severe pulsating left-sided headache, nausea, dizziness and motor weakness of upper and lower limbs associated with a combination of confusion, widespread paresthesia, and visual aura. Typical aura symptoms generally resolved within 4 hours, while motor impairment lasted up to a maximum of 7 days. At the moment of the first evaluation, the patient referred she had suffered of 15 attacks of migraine without aura and 2 attacks of HM per month in the previous 3 months. No family history of HM was reported. Brain and spinal cord MRI and electroencephalography were normal. Laboratory investigations and a full thrombotic risk evaluation showed no evidence of a genetic or acquired coagulation disorders. The sole relevant abnormality was the increase of antiphospholipids IgM (15.3 MPL-UI/mL). Genetic testing for CACNA1A, ATP1A2 and SCN1A mutations were negative. However, a heterozygous variant of uncertain significance of PRRT2, inherited from the mother, was detected. The patient had been treated with several migraine prophylactic drugs over the years with limited to no benefit. A preventive therapy with lamotrigine, titrated to 100 mg daily, was prescribed. A 9-month treatment reduced the number of both migraine without aura and HM attacks by 50%, with no side effects. Conclusions: This case supports efficacy of lamotrigine in the prophylactic treatment of SHM. The detection of a variant of uncertain significance in a gene involved in synaptic glutamate release suggests that other unknown genetic alterations or environmental factors may play a role in SHM expression. Background: Migraine is considered a complex disease, a variable disorder of nervous system function that has a genetic background, yet the final phenotypic outcome largely depends on the individual's environment and lifestyle. In particular, there is a clear relationship between menstruation cycle and the onset of migraine. In fact, over 50% of migraine women suffer from perimenstrual attacks, that are more serious, lasting and resistant to the treatment than non-menstrual migraine attacks [1] . We hypothesized that serum proteome analysis could help to identify potential biomarkers of menstrually-related migraine (MM) and postmenopausal migraine (PMM). Methods: We analyzed and compared the serum proteomic profile of three groups: women suffering from MM (n=15), post-menopausal women suffering from migraine without aura (n=15) and non-headache control females (n=14). The enrolled migraineurs were patients afferent to the Headache Centre of Modena University Hospital; the control females were friends or relatives of the above patients. All women gave their written consent and the Ethical Committee of Modena approved the study. Serum samples obtained from each study participant were subjected to bi-dimensional gel electrophoresis (2-DE) coupled to mass spectrometry (MS) analysis for protein identification. The 2D-gel maps were examined by the PDQuest software, to detect the differentially expressed protein spots between the different groups [2] . Results: A total of 13 significantly different protein spots were revealed in migraine women compared to controls. Of these proteins, most (n=10) resulted increased in migraineurs vs controls, while only 3 proteins were decreased. Specifically, the greater expression differences involved the up-regulation of transthyretin in PMM and the down-regulation of apolipoprotein A1 in MM. Other proteins, such as prothrombin, serum amyloid P-component and Ig-k-chain C region, were found significantly overexpressed in migraine sufferers in comparison to controls, while one spot, recognized as serum amyloid A-4 protein, resulted decreased. Conclusions: The serum proteome of migraine women showed proteins characteristic of cell damage, oxidative stress and lipoperoxidation, as well as acute phase proteins and inflammation markers. This pilot study demonstrates the ability of proteomics to reveal differences in protein expression between women suffering from MM and post-menopausal women suffering from migraine without aura against non-headache women. Further analysis will be carried out to expand and confirm these preliminary results. (qEEG) has been helpful in this field. Main results were or increased focal slowing waves or abnormalities in power spectral values due to an increasing of slow activity or decreased alpha activity in the posterior leads or in all cortical regions. Unlike Walker found an excess of high frequency beta activity [1] . However most of these studies are based on the observation of EEG activity during the post-ictal period of migraine attack. Here we report EEG signal during the painful attack in a patient suffering of migraine with aura. Case report: A 15-year old girl was admitted to our neurological consult, because, a few hours before, she had complained the start of visual and subsequently sensory aura followed by severe unilateral pulsating pain. At the time of the consult, after initially performing an EEG, she complained only moderate pain when she began to experience the same symptoms that had just preceded the onset of the aura. Immediately another EEG exams was performed during the aura until its conclusion. Subsequently the patient was hospitalized and underwent several investigations without significant anomalies. A quantitative EEG analysis was applied to two performed EEG. Recorded trace was cut in time blocks of 20 seconds each one during the aura and the pain phase.
Results: Data were analysed considering the delta, theta and alpha activities. QEEG show a decrease of slow rhythms during the aura in the posterior leads and a subsequent immediate increase in the subsequent pain phase. Fast rhythms were equally represented in both phases. Conclusions: The EEG patterns observed in our migraine patient seem to suggest the possible changes in cortical EEG rhythms between the two main phases of migraine attacks (aura and pain phases), to support the physiological connection between migraine and brain activity and may shed new light on migraine pathophysiology. Reference 1. Walker JE (2011) QEEG-guided neurofeedback for recurrent migraine headaches. Clin EEG Neurosci (1) Background: Migraine is a disabling primary headache disorder which may interfere with patients' psychological status, quality of life, and functioning. Nevertheless, migraine evaluation according to psychosomatic principles, including psycho-social factors which might affect its course has been poorly performed. The present study was aimed at evaluating psychosomatic, psychosocial, and psychological variables as potential risk factors for migraine. Methods: A cohort study design was applied. Two-hundred subjects were enrolled at the Headache Center of the Careggi University Hospital (Florence, Italy): 100 subjects had a diagnosis of chronic migraine (CM) and 100 had a diagnosis of episodic migraine (EM). One-hundred healthy subjects (HS) were also enrolled form the general population of Central Italy as healthy controls (ratio case: (2); p = 0.016); Type A Behavior (CM = 8; EM = 13; HS = 8; χ 2 (df) = 7.14(2); p = 0.028), Irritable Mood (CM = 13; EM = 4; HS = 10; χ 2 (df) = 5.13(2); p = 0.077) and Alexithymia (CM= 5; EM = 10; HS = 12; χ 2 (df) = 3.18(2); p = 0.204). Among the variables taken into account, higher levels of mental pain (OR = 1.26; 95% CI = 1.04-1.53) or more severe depressive symptoms were found as risk factors for CM as compared to healthy subjects; mental pain (OR = 1.33; 95% CI = 1.10-1.62) was higher in CM as compared to EM. No risk factors were found for EM towards healthy subjects. Conclusions: CM patients exhibit a significantly higher risk than healthy subjects and EM patients with regard to series of psychosomatic variables (i.e., mental pain and depressive symptoms), whereas there was no difference between EM patients and healthy controls. Thus, mental pain and depressive symptoms are psychosomatic variables deserving attention in migraine patients. Objectives: To assess relation between anxiety sensitivity and headache trigger susceptibility. Background: Individual with recurrent headache exhibit fear of pain and avoidance of behaviors or stimuli that may instigate or perpetuate their headache pain. Fear of pain recently has been shown to be strongly predicted by anxiety sensitivity, or the fear of benign bodily sensations stemming from the belief that these sensations have harmful consequences. However, studies have not explored relations between anxiety sensitivity and susceptibility to headache triggers, a needed area of research given centrality of avoidances models of chronic pain and potential implications for intervention. Methods: One hundred and sixty-nine headache sufferers retrospective chart review 1/10/2018 -2/2/2019 (57% females 33% men, age 18-75 yrs mean 37.2, primarily episodic migraine and ETTH) completed battery of measures including the Hamilton Anxiety and questions about headache triggers; associations were quantified between the three subscales of ASI -3 (concerns cognitive, physical, social) and trigger variables using generalized. Results: Anxiety sensitivity was strongly and positively associated with the total number of endorsed triggers (ps<0.001) estimates of how often important trigger was encountered (ps<0.001), and the perceived potency of an important trigger (p<0.0001). Physical concerns were associated with all three aspects of these trigger perceptions, while cognitive concerns were related to the number of triggers and frequency of encounter only. Social concerns were uniquely associated with sensitivity to exercise and alcohol as triggers. Conclusions: Headache sufferers with high anxiety sensitivity perceive themselves to have more headache triggers, more frequent exposure to triggers, and higher potency of triggers (probability of headache following exposure) than individuals lower on anxiety sensitivity. Anxiety sensitivity may function as a previously unknown but important factor and target of behavorial therapy for triggers management. Objective: The ability to attribute mental states to oneself and others is an important aspect of social cognition, also known as Theory of Mind (ToM). The ability to make social cognitive inferences is indeed crucial for successful social behaviours because they mediate an understanding of the intentions and dispositions of others and lead to the correct prediction of behaviour. Previous evidences have shown an association between ToM and Alexithymia (A), which refers to the inability to identify and express emotions, as well as pathological scores in these aspects in chronic migraine. Given the relevance of Theory of Mind in social interactions, it is important to assess it by using tests approximating the demands of everyday life social cognition, which is lacking in previous studies. The present study is aimed to evaluate whether chronic migraine is associated to deficit in ToM and in other aspects of social functioning, by using a video-based instrument, the Movie for the Assessment of Social Cognition (MASC), requiring subjects to make inferences about video characters' mental states.
Methods: 40 patients suffering from chronic migraine (CM) (79.5% female, Age: 47.3±11.1) and 37 patients suffering from episodic migraine (EM) (83.8% female; Age: 41.0±11.4) were evaluated using a battery of ToM tasks comprising the MASC and the Reading the Mind in the Eyes Test (RMET), as well as questionnaires on their social functioning. Chronic migraine diagnosis was operationally defined according to ICHD-IIIβ. Data were analyzed with analysis of variance. Results: Compared with EM, CM patients had significantly lower scores in the MASC (CM=17.7±14.7, EM =22.9±14.0, p<.05), and these differences resulted also when distinguishing between cognitive (CM=9.9±9.4, EM =14.6±9.1, p< .05) and affective (CM=5.8±5.5, EM =8.3±5.2, p<.05) components. EM also had higher scores in the RMET (CM=21.7±3.1, EM =24.4±3.8, p<.005), and believed to be abler to understand ones and others' feelings in comparison to chronic migraineurs. Conclusions: Our results indicate that CM patients have more difficulties in understanding others' mental states than EM, which is highlighted also by tasks reflecting everyday life competences. This evidence suggests the existence of a link between this chronic condition and social competent behaviours and abilities. Background: Depression is common in CM and contributes to the already substantial burden of disease. Fremanezumab (TEV-48125), a fully humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention. Methods: In this Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, eligible patients aged 18-70, with prospectively confirmed CM (≥15 headache days and ≥8 migraine days per month) were randomized 1:1:1 to receive subcutaneous injections of fremanezumab quarterly (675 mg at baseline; placebo at Weeks 4 and 8), fremanezumab monthly (675 mg at baseline; 225 mg at Weeks 4 and 8), or matching placebo over a 12-week treatment period. Post hoc analyses evaluated changes in headache and migraine frequency and depression in patients with moderate to moderately severe depression (score of 10-19 on the 9-item Patient Health Questionnaire [PHQ-9]) at baseline. Results: Almost 20% (219/1130) of randomized patients had moderate to moderately severe depression at baseline (quarterly, n=74; monthly, n=88; placebo, n=57). As in the overall study population, fremanezumab-treated patients in this subgroup had significant reductions from baseline in the mean number of monthly headache days of at least moderate severity (quarterly: −5.4 ±0.79; monthly: −5.6±0.75) versus those who received placebo (−2.2±0.84) during the 12-week treatment period (both, P<0.001), with effects observed as early as Week 4 (P<0.0001). Similar treatment differences were observed for change in the mean number of migraine days (P<0.001). Fremanezumab also reduced the mean PHQ-9 score from baseline to Week 12 (quarterly: −10.5±0.68; monthly: −9.5±0.63) versus placebo (−8.7 ±0.71); the quarterly group reached significance (P<0.05). Conclusions: Fremanezumab demonstrated efficacy in preventive treatment of CM in patients with comorbid moderate to moderately severe depression, reducing migraine and headache frequency and improving depression.
Role of maternal stress and alexithymia in children's migraine severity and psychological profile Objective: A growing body of literature explored the role of mother-child interaction in children's migraine severity. Recent studies showed that patients' attachment style and maternal alexithymia traits may impact on psychological profile and pain expression in children/adolescents suffering from migraine. Very few studies focused on the relationship between maternal stress, their children's psychological profile and migraine severity. Aims of our study were to explore the role of maternal parenting stress and alexithymia on: 1) their children's headache severity (frequency); 2) maternal perception of children's psychological conditions and 3) children's psychological profile. Methods: We studied 51 migraineurs (mean age 11.6 ± 2.1 years; 22 M and 29 F). Patients were divided in two groups according to headache attack frequency: 1) high frequency (from weekly to daily episodes) and 2) low frequency patients (≤3 episodes per month). Maternal stress and alexithymia levels were evaluated respectively by PSI-SF and TAS-20 questionnaire. SAFA "Anxiety" and "Depression" scales were used to explore children's psychological profile. To evaluate maternal perception of children's psychological conditions CBCL 6/18 was employed. Results: We found a correlation between maternal stress and CBCL Internalizing (p=0.00), Externalizing (p=0.00) and Total scales (p=0.00). A positive correlation has been identified between mothers' PSI Total score and SAFA-D Total score (p=0.03). In particular, a positive correlation was found between BParental distress^and children's SAFA-D BFeeling of guilt^subscales (p=0.04). Maternal stress and alexithymia did not show significant differences among the two migraine frequency groups (p>0.05). However, in the high frequency group, PSI Total score showed a positive correlation with Internalizing scale (p=0.00). No relationships were found between TAS-20, CBCL, SAFA and migraine frequency. Conclusions: Maternal stress has no relationship with children's migraine frequency. However, it shows a relationship with maternal perception of children's psychological profile and patients' depressive symptoms, which in turn may impact on migraine severity.
Coping strategies in migraine without aura: a cross-sectional study Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences and 2 Department of Psychology, University of C a m p a n i a BL u i g i Va n v i t e l l i^, N a p l e s , I t a l y ; e -m a i l : fa.scottodiclemente@gmail.com
Background: In the context of causal relationship between stress and migraine, coping strategies aim to manage stressful life events and reduce the distressing emotions connected to them. Methods: Fifty-two consecutive patients with migraine without aura (MwoA ) and fifty-two healthy controls (HC) completed three self-report questionnaires assessing a broad range of coping (cognitive and behavioural) strategies: the Coping Orientation to Problems Experienced (COPE), the Coping Inventory for Stressful Situation (CISS) and the Proactive Coping Inventory (PCI). Moreover, the Perceived Stress Scale (PSS), a scale measuring self-perception of stress, global cognitive functioning, depressive symptoms, apathy, state and trait anxiety was administered to all participants. Results: No significant difference was found on the scales and subscales of PCI and CISS as well as in the PSS between MwoA patients and HC. However, the two groups showed different scores in the subscale Bturning to religion^of COPE (21.58 ± 5.30 in migraineurs vs 23.70 ± 4.60 in HC, p=0.003). A significant negative correlation of turning to religion score with HIT-6 score was found. Conclusions: The present study revealed that MwoA patients show a significantly reduced use of the Bturning to religion^approach, an emotion-focused coping strategy. Although migraine patients appeared to be less oriented to transcendent (that means a reduced utilization of an adaptive coping strategy) they did not perceive daily living more stressful than HC. Finally, the reduced utilization of the Bturning to religion^coping strategy is associated with a great impact of migraine on ability to function on the job or at school, at home and in social situations in migraine patients. Background: The MIG-SCOG is a questionnaire to assess self-reported subjective cognitive symptoms during migraine attacks, consisting of 9 items related to executive functions and language. The aim of this study was to evaluate the psychometric properties of the Italian version of the MIG-SCOG (I-MIG-SCOG) in patients with migraine without aura (MwoA). Methods: The MIG-SCOG was translated into Italian. The first draft of the questionnaire was administered to 20 Italian healthy subjects to assess its comprehensibility. Then, the final I-MIG-SCOG was completed by 125 MwoA patients. To assess divergent validity, MwoA patients underwent Montreal Cognitive Assessment, Beck Depression Inventory and Apathy Evaluation Scale. Results: The final I-MIG-SCOG was easily comprehensible. There were no missing data, no floor and ceiling effects; mean I-MIG-SCOG score was 7.24±3.78; Cronbach's alpha was 0.814. The I-MIG-SCOG showed good divergent validity (i.e. poor correlation between I-MIG-SCOG and MoCA, BDI and AES). Conclusions: The MIG SCOG is confirmed to be a reliable patientcentered and disease-related instrument to identify cognitive symptoms during migraine attacks also in Italian patients. The I-MIG SCOG should be used in the clinical practice as well as in the research scenario to evaluate the contribution of cognitive symptoms on migraine burden and to monitor the divergent effects of symptomatic treatments on cognitive functions in migraine patients.
Neuropsychological disorders in migraineur children
A. Onofri, E. Tozzi Neuropsychiatric Clinic, Department of life, Health and Environmental Science, University L'Aquila, Italy; e-mail: agnese.onofri@graduate.univaq.it Background: Among the comorbidities of the migraineur children and adolescents there are some neuropsychological disorders. Many authors have demonstrated this relationship, although not uniquely. This research aims to evaluate this comorbidity depending on the diagnosis of the migraine type. Methods: One hundred and six children, aged 4-17 years, 62 F and 44 M form the sample. The patients were recruited consecutively during 2018 at the Abruzzo Regional Headache Center, Childhood Age-Dep. Child Neuropsychiatry-Hospital San Salvatore L'Aquila. The sample was divided according to ICDH-III criteria into 2 groups: Migraine with Aura (MwA) and Migraine without Aura (MwoA). We used the following tests: BLeiter-R^for sustained attention and BCorsi test^for spatial-visual short memory; the BCBCL 6/18^for emotional-behavioral disorders. Statistical analysis was done with Fisher test. Results: Seventy-six children suffering from MwoA and 30 from MwA. They had a mean age of 13 years and the mean age of onset of headache was 9 years. Twelve children with MwoA had an attention deficit and 2 mnesic deficits, the remaining sample did not seem to show such alterations. Twenty-four children showed positivity for internalizing disorders and 3 for externalizing disorders. Eight children with MA had an attention deficit and 2 had a mnesic deficits. Twenty children had positivity for internalizing disorders and 2 externalizing disorders. Therefore comparing the two groups, MwA had a higher degree of disability in sustained attention and psychopathology for internalizing disorders. Comparing the percentages, children suffering from migraine with aura (MwA 36% Vs MwoA 28%) report greater impairment of attentive skills and more comorbidity with internalizing disorders (MwA 66% Vs MwoA 56%). The statistical analysis of the data did not show statistically significant results, therefore we can only support a qualitative observation of the data found. Conclusions: Mood disorders can play an important role in neuropsychological performances. Neuropsychological disorders seem to be influenced by the presence of anxiety. Introduction: Vitamin D is very important in mineral homeostasis but is also an anti-inflammatory hormone and has a negative effect on proliferation of mast cells and can stimulate nitric oxide (NO) [1] . Therefore vitamin D has an important role in cardiovascular disease [2] . Recently growing but conflicting evidence has shown a possible relationship between vitamin D and chronic or recurrent painful conditions such as migraine [3] . Objective: Our aim was to determine 25(OH)D level in our migraineurs patients and correlate them to age and headache duration. Material and methods: We collected, in a small preliminary analysis, 25(OH)D level in 50 consecutive migraineurs patients belonging to our headache centre, in San Luca Hospital, Vallo Della Lucania. 25-Hydroxy vitamin D [25(OH)D] plasma levels were measured by MicroVue 25-OH Vitamin D EIA. 40 patients were women, 10 were male; 44 were diagnosed with migraine without aura, 6 had fulfilled criteria for migraine with aura; mean age was 39.9±12.7 years; mean disease duration was 10.4±10.3 years. Results: Mean vitamin D serum level was 18.7±5.3 ng/ml, denoting a state of insufficiency. Among our 50 patients, only 6 have serum level above 30 ng/ml (sufficiency); most patients (40 out of 50) showed serum level among 10 and 30 ng/ml, while in 4 patients serum level was less than 10 ng/ml. All these last three patients were diagnosed with migraine without aura. Conclusions: Vitamin D insufficiency is a frequent finding in our migraineurs patients, but we cannot postulate a definite relationship between vitamin D deficiency and migraine. We suggest that this conclusion needs to be supported with randomised clinical studies containing a larger number of samples and controls. Moreover, intervention studies are required to find out if supplementation of vitamin D and calcium is effective in patients with migraine. Background: Resting-state functional MRI studies suggest that abnormal functional integration between interconnected cortical networks characterizes the brain of migraineurs. The aim of this study is to investigate the functional connectivity between the hypothalamus, the brainstem -the supposed generators of migraine-, and the areas that encompass the following networks involved in the pathophysiology of migraine: the default mode network (DMN) and the dorsal attention system (DAS). Methods: Twenty patients with chronic migraine (CM) without medication overuse and 20 healthy subjects (HS) were prospectively recruited. All study participants underwent 3T MRI scans using a 7.5-minute resting state protocol. Using a seed-based approach, we performed a ROI to ROI analysis choosing hypothalamus as seed and areas belonging to the DMN and the DAS, and brainstem as target region of interests. Results: Compared to HS, CM patients showed significant increased neural connectivity between the hypothalamus and brain areas belonging to DMN and DAS. We haven't detected any connection abnormalities between the hypothalamus and the brainstem. The correlation analysis showed that the severity of migraine headache correlates positively with the connectivity strength of the hypothalamus and negatively with the connectivity strength of the middle prefrontal cortex, which belongs to the DMN. Conclusions: These data provide evidence for hypothalamic involvement in large-scale reorganization at the level of the functional networks during chronic migraine and in proportion with the severity of perceived migraine pain.
Chronic migraine patients show a different profile of the white matter fiber bundles compared to healthy subjects Background: In recent years, several studies have shown that the migraine brain is characterized by an alteration of the intrinsic functional connectivity of different cortical networks. Little is known about the microstructural integrity of the fiber bundles that interconnect them. Here, we have investigated intracerebral fiber bundles through the most modern techniques of diffusion tensor imaging (DTI) analysis. Methods: For this study, we prospectively enrolled 19 episodic migraineurs (EM) between attacks, 18 chronic migraineurs (CM) without overuse of symptomatic drugs and 18 healthy subjects (HS). All subjects underwent diffusion tensor imaging (DTI) scans using 3T MRI. We investigated the microstructure of white matter using tract-based spatial statistics (TBSS) analysis to calculate diffusion metrics, including fractional anisotropy (FA), axial (AD), radial diffusion (RD) and mean diffusion (MD). All analysis was corrected for age and gender. series of neuropeptides including calcitonin gene-related peptide (CGRP), adrenomedullin, amylin, pituitary adenylyl cyclase activating peptide (PACAP) and vasoactive intestinal polypeptide (VIP), which have been found to provoke or not provoke migraine-like attacks in patients, to elicit or not to elicit delayed and prolonged periorbital mechanical allodynia (PMA) after their injection in the periorbital skin of mice. Methods: CGRP, adrenomedullin, amylin, PACAP and VIP were administered by local injection in the periorbital area of C57BL/6J mice. Spontaneous nociception was assessed by measuring the time (seconds) that the animal spent face rubbing the injected area with its paws, mechanical allodynia was assessed with the von Frey filament assay. Antagonists were administered by local and systemic injections. Results: The periorbital injection of CGRP, even at the highest dose, did not evoke an acute spontaneous nociceptive response but, it did cause a robust, dose-dependent and sustained PMA lasting 4 hours after the injection. Systemic intraperitoneal or local injection of the CGRP receptor antagonist, olcegepant, or the monoclonal anti-CGRP prevented PMA. Local administration of adrenomedullin or amylin at the same proallodynic dose of CGRP, was unable to produce any measurable acute nociceptive response and PMA, over the entire period of observation (6 hours). Local injection of PACAP, which did not provoke any detectable spontaneous nociceptive behaviour even at the highest dose, induced a marked, dose-dependent and sustained (1-6 hours) PMA prevented by pretreatment with the selective PACAP receptor antagonist, PACAP6-38. VIP was unable to produce either acute nociception or PMA. Conclusions: The correspondence between neuropeptides that provoke (CGRP; PACAP), or do not provoke (VIP), migraine-like attacks in patients and periorbital allodynia in mice suggests that the study of allodynia in mice may provide information on the proalgesic mechanisms of migraine-provoking agents in humans. Results underline the ability of migraine-provoking substances to initiate mechanical allodynia by acting on peripheral terminals of trigeminal afferents. Background: Despite the growing body of advanced studies investigating the neuronal correlates of pain processing in patients with migraine without aura (MwoA), only few similar studies have been conducted in patients with migraine with aura (MwA). Therefore, we aimed to explore the functional brain response to trigeminal noxious heat stimulation in patients with MwA. Methods: Seventeen patients with MwA and fifteen age-and sexmatched healthy controls (HC) underwent whole-brain blood oxygen level-dependent (BOLD) fMRI during trigeminal noxious heat stimulation. To examine the specificity of any observed differences between patients with MwA and HC, the functional response of neural pathways to trigeminal noxious heat stimulation in patients with MwA was compared with eighteen patients with MwoA. Secondary analyses investigated the correlations between BOLD signal changes and clinical parameters of migraine severity. Results: We observed a robust cortical and subcortical pattern of BOLD response to trigeminal noxious heat stimulation across all participants. Patients with MwA showed a significantly increased activity in higher cortical areas known to be part of a distributed network involved in advanced visual processing, including lingual gyrus, inferior parietal lobule, inferior frontal gyrus and medial frontal gyrus. Moreover, a significantly greater cerebellar activation was observed in patients with MwA when compared with both patients with MwA and HC. Interestingly, no correlations were found between migraine severity parameters and magnitude of BOLD response in patients with MwA. Conclusions: Our findings, characterized by abnormal visual pathway response to trigeminal noxious heat stimulation, support the role of a functional integration between visual and trigeminal pain networks in the pathophysiological mechanisms underlying migraine with aura. Moreover, they expand the concept of Bneurolimbic-pain network^as a model of MwoA including both limbic dysfunction and cortical dys-excitability. Indeed, we suggest a model of Bneurolimbic-visual-pain network^in MwA patients, characterized by dysfunctional correlations between pain-modulating circuits not only with the cortical limbic areas but with advanced visual areas as well. Furthermore, the abnormal cerebellar response to trigeminal noxious heat stimulation may suggest a dysfunctional cerebellar inhibitory control on thalamic sensory gating, impinging on the advanced visual processing cortical areas in patients with MwA.
Default mode networks abnormalities predict the cutaneous allodynia in patients with episodic migraine without aura Background: Approximately two-thirds of patients with migraine without aura (MwoA) complain of cephalic or even extracephalic cutaneous allodynia (CA) during migraine attacks. CA is a clinical sign of central nociceptive pathway sensitization and independent predictor for migraine chronification. This article aims to investigate if abnormalities of default mode network (DMN) functional connectivity could predict the development of cutaneous allodynia in patients with MwoA. Methods: Thirty-seven patients with MwoA were recruited between 2009 and 2015 and underwent whole-brain blood oxygen level-dependent (BOLD) fMRI. All these patients have been followed over a three years period and then divided into 2 groups based on whether or not cutaneous allodynia was developed. Then, we compared functional connectivity within the DMN in 20 patients with MwoA who have developed CA versus 17 patients with MwoA who have not developed CA and 19 sex-and age-matched healthy controls (HC). Furthermore, we assessed the correlation between functional connectivity within DMN and all clinical parameters of disease severity. Results: We observed a significantly lower functional connectivity within posterior cingulate cortex (PPC)/precuneus in patients with MwoA who have developed CA when compared to patients with MwoAwho have not developed CA and HC. Discussion: PCC is known as a key hub of DMN with a prominent antinociceptive functions, deactivated by experimental pain in HC but not in patients with chronic pain condition which show a reduced brain posterior cingulate cortex volume. Interestingly, an increased functional connectivity between the precuneus and the posterior cingulate cortex regions of the DMN has been observed in patients with MwoA. We suggest that DMN abnormal functional connectivity could represent a prognostic imaging biomarker for the incipient development of CA in patients with episodic MwoA.
Safety and efficacy of erenumab for the preventive treatment of migraine: a real-world, prospective, observational study from a Headache Center C. Tiseo, R. Ornello, I. Frattale, M. Martella, F. Pistoia, S. Sacco Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy; e-mail: cindy.tiseo@gmail.com Background: Clinical trials have shown the efficacy and safety of monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor for migraine prevention. We aimed to evaluate the safety and efficacy of erenumab in routine clinical use in a sample of patients with high frequency episodic (EM) and chronic migraine (CM). Methods: We included consecutive patients with EM (≥ 4 monthly migraine days, MMD) or CM aged ≥18 years admitted to our Regional Headache Referral Center from January to April 2019 and treated with erenumab monthly injections. We recorded baseline characteristics including headache features, headache frequency and duration, drug abuse, and prior preventive treatment failure. We evaluated change in mean MMD, number of acute medication use, and pain intensity according to the Visual Analog Scale (VAS) from baseline to week 8. Results: We included 25 subjects (22 women; mean age±SD, 46.89±11.20 years); 1 had EM and 24 CM (72% with medication overuse). All patients received erenumab 70 mg at the first injection, and 2 patients received erenumab 140 mg at the second injection. Seven (28.0%) patients failed 1, and 18 (72%) failed 2 or more prior preventive treatments; 13 patients with CM (54.2%) had failure of onabotulinumtoxinA. In 10 patients erenumab was started as an add-on treatment. Compared to baseline, change in MMD was -2.23±2.79 days at week 1 (P=0.003), -8.41±8.62 days at week 4 (P<0.001), and -13.00±6.91 days at week 8 (P<0.001); change in acute medication use was -2.20±2.67 days at week 1 (P<0.001), -8.88±10.01 days at week 4 (P=0.002), and -14.22±8.83 days at week 8 (P=0.001); change in pain intensity was -1.31±1.55 VAS points at week 1 (P=0.010), -1.25±1.77 points at week 4 (P=0.013), and -1.67 ±1.50 at week 8 (P=0.010). Significant improvements in MMD, acute medication use, and pain intensity were observed also considering the 15 patients who stopped the other preventive treatments after starting erenumab. Six (24.0%) patients reported 8 adverse events, including pruritus (4.0%), wheal at injection site (4.0%), constipation (12.0%), aerophagia (4.0%), fatigue (4.0%), and flu-like syndrome (4.0%); none reported adverse events that led to treatment discontinuation. Conclusions: In the real-life setting the benefits of erenumab appeared better than expected by the results of clinical trials. Possible explanations may rely on the different characteristics of patients but possibly also on the placebo effect. Moreover, our findings confirm the rapid onset of efficacy of erenumab and the lack of necessity of detoxification before treatment of patients with medication overuse.
The behaviour of Intrinsic Connectivity Networks in episodic and chronic migraine Background: Changes in the basal behavior of intrinsic connectivity networks, including the Default Mode Network (DMN) and the Salience Network (SN) may be associated with the occurrence of Episodic Migraine (EM) and the process of transformation toward a chronic form. The aim of the present study is to investigate functional connectivity (FC) within the SN and the DMN in EM and chronic migraine (CM), in order to identify any functional brain connectivity changes associated with chronification. Methods: Patients consecutively referring to the Regional Headache Centre of L'Aquila with a diagnosis of migraine were screened for the inclusion in the study. The diagnosis of EM or CM was made according to the criteria of the International Classification of Headache Disorders (ICHD-III beta version). Thirty-five women with EM (mean age 44.6 ±9.1), 32 women with CM (mean age 44.9±9.4) and 28 healthy women (mean age 44.2±10.3) were included. All subjects underwent a neuroradiological assessment through a 3 Tesla Magnetic resonance Imaging (MRI) scanner (Discovery MR750w). Resting-State fMRI data were analysed by means of a seed-based approach, using four and six different seeds, sampling the main hubs of the DMN and SN respectively. Results: SN in CM patients was characterized by a reduced FC between left supramarginal gyrus and cerebellar tonsils, compared to HC (p=0.001), and between the left anterior insula and the midcingulate cortex, compared to EM patients (p=0.0007). EM patients showed extensive alterations in the DMN compared to HC, mainly due to reduced FC of the frontal DMN hub with the precuneus (p=2·10-5) and the right lower parietal (p=5·10-5) cortex. Conclusions: A reduced FC among crucial hubs of the SN, which is responsible for switching between the DMN and the central executive network through the selection of internal and extrapersonal stimuli, may be associated with the process of migraine chronification. On the other hand, changes in the DMN, which mediates self-reference and own emotional states, may be a neural marker of earlier EM.
Visual cortical excitability in fibromyalgic and migraine patients: a study with sound induced flash illusion Background and aims: Excitability of pain-processing areas and response to incoming somatosensory stimuli are abnormally enhanced in Fibromyalgia (FM) and in migraine. To explore if such facilitation represents a more general sensorial activation not strictly related to pain, we evaluated excitability of visual cortex, an area not directly involved in pain processing, through Sound-Induced Flash Illusion (SIFI). SIFI are cross-modal illusions, strictly dependent upon visual excitability, where visual perception is influenced by auditory input. When a single flash is accompanied by multiple beeps, it is perceived as multiple flashes (fission illusion), conversely when one flash is accompanied by more beeps, more flashes are seen (fusion illusion). SIFI are reduced when visual cortical excitability increases. Methods: We performed SIFI in five FM patients, five migraine with aura (MWA) patients and five without aura (MWoA) patients and 5 healthy controls (HC). Throughout the test, 0 -four flash were presented on a monitor together with 0-4 beeps delivered by loudspeakers, in different combinations. The observer's task was to judge the number of flashes seen. Results: Data do not show a significant reduction in fission illusions in the comparison between MWoA and HC (p>0.05). A significant reduction is seen when FM patients are compared to HC and MWoA patients (particularly when one flash is accompanied by two, three, or four beeps, p<0.01), but also to MWA (when one flash is accompanied by three or four beeps, p<0.05). MWA patients have a significant reduction compared to HC and MWoA (when one flash is accompanied by two, three or four beeps, p<0.05) Conclusions: Our results suggest an increased visual excitability especially in FM patients even greater from that observed in MWA patients. No significant results were shown for MWoA patients in comparison to HC. This could shed more light on pathophysiological mechanisms of these diseases and the relations between pain and cortical connectivity likely opening also new ways for treatment. SIFI represent an easy and effective tool to explore cross-modal audio-visual perception and visual cortical excitability in FM and MWA patients.
The study of sensorimotor integration in migraine reveals basal ganglia disfunction related to consumption of medications taken for acute headache attack Objectives: Neurophysiological and neuroimaging studies have shown dysfunctions of brain areas responsible for multisensory integration in migraine. Among these areas, the basal ganglia, the thalamus, and the primary somatosensory area (S1) play a major role in sensorimotor integration. One of the experimental approaches to assess mechanisms of sensorimotor integration and sensory gating is to measure the somatosensory temporal discrimination threshold (STDT)-i.e. the shortest interval at which an individual recognizes two stimuli as separate in time-at rest and during movement execution. STDT involves the activation of the subcortical network signalling salient events and S1. Testing STDT during movement execution (sensory gating) involves basal ganglia/ thalamus interplay. Here we investigated STDT tested at rest and during index finger abductions in patients with migraine without aura during and outside the attacks. Methods: We tested STDT in 24 migraine without aura patients, 16 in between attacks (MO) and 9 during an attack (MI). The patients were compared with a group of 30 healthy volunteers (HVs). STDT was tested at rest and during index finger abductions (at movement onset and 100, 200, and 500 milliseconds afterwards). Results: Compared to HV, basal STDT values and those obtained 500 ms after movement onset (when movement is already ceased) were significantly reduced in MI patients (p=0.013), with MO patients falling in between HV and MI. When data of MO and MI patients were combined, Pearson's test disclosed that STDT value tested at rest and that obtained 500ms after movement onset correlated negatively with monthly number of medications taken for acute headache attack. No significant differences or correlations were instead observed in STDT values tested during movement executions. Conclusions: Here we have reported reduced STDT values in patients with migraine during an attack. In addition, we have observed a close relationship between electrophysiological abnormalities and the number of acute medications consumed monthly. Further studies are needed to understand whether these changes suggest an abnormally hyperactive subcortical network signalling salient events during migraine attack, which would send excessive information to S1, or to medication-induced neural adaptation promoted by changes in basal ganglia neurotransmission. Background: For complex disorders such as migraine, both genetic and environmental components play an important role in disease pathogenesis. Epigenetic markers are heritable changes in phenotype or gene expression in the absence of changes in DNA sequence. DNA methylation is the most common type of epigenetic modification, and plays a key role in several disorders as cancer and neurodegenerative disorders. Changes in global DNA methylation have been associated with environmental factors. To date, little is known about DNA methylation in migraine. Several studies have shown that the neuropeptide calcitonin generelated peptide (CGRP), encoded by CALCA gene, has a key role in migraine pathogenesis, and successful new drugs for migraine prophylaxis target CGRP. The aim of the study was to evaluate DNA methylation of CALCA gene in patients with migraine. Methods: Twenty-two patients with episodic migraine (15 females, 7 males; mean age± SD: 39.7±13.4 years) and 20 controls (12 females, 8 males; mean age± SD: 40.5±14.8 years) were recruited for the study at the Department of Neuroscience, University of Torino, Italy. The diagnosis of migraine was made according to ICHD-III criteria. All samples were studied by direct bisulfite sequencing. Cytosine-to-thymine conversion by sodium bisulfite was performed using EZ DNA Methylation™ Kit. Results: DNA methylation in both patients and controls was more pronounced at 5' flanking region. No overall difference was found in the global methylation of CALCA in patients with migraine and controls. Interestingly, stratification analysis showed that in migraineurs the methylation level was significantly lower in 2 out of the 6 analysed CpG islands p=0.04; p=0 .04, respectively). Finally, CpG unit at -302 correlates with age at onset of migraine (p=0.038). Conclusions: This study provides the first evidence that DNA methylation of CALCA gene promoter could play a role in migraine. Global DNA methylation of CALCA gene in migraineurs does not differ from controls. However, DNA methylation profile in two CpG units (-302 and -256) of the promoter region is lower in migraineurs in respect to controls. Importantly, the -256 unit is located into a 7 nucleotides region containing a cAMP responsive element which binds CREB, a cellular transcription factor. Further studies with larger sample size are needed to confirm these preliminary results and to evaluate the potential role of methylation in the clinical response of migraine therapy. Background: The pathogenesis of high frequency headache in children is multifactorial and often needs a multidisciplinary approach that includes both pharmacologic and non-pharmacologic therapies, such as biobehavioural management, agopuncture, osteopathic treatment. Osteopathic treatment results effective in some paediatric conditions, but in primary headache the possible efficacy is still unknown. The aim of this study is to evaluate the effectiveness of osteopathic manipulative therapy in supporting prophylactic medications in paediatric patients with high frequency headache. Methods: This is a randomized controlled double blind study in collaboration with BScuola Superiore di Osteopatia Italiana^and is still ongoing. We recruited patients who referred to the Headache Centre of Regina Margherita Hospital in Turin, aged 8-18 years, with high-frequency headache, in which prophylactic medication for at least two months had failed. Patients were randomised into two groups: the Osteopathic Manipulative Therapy (OMTh) group and the Light Touch Therapy (LTTh) group. The LTTh retained the same areas used for osteopathic approach but avoided prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force. Both treatment groups received 5 therapies: the first at baseline, the second after 1 week, the third after 3 weeks, and then 2 more treatments on a monthly basis. The outcome measures were: reduction on frequency of headache episodes (primary outcome), reduction of analgesic use, improvement of quality of life and adverse events caused by OMTh (secondary outcomes). These data were evaluated by headache diary and a quality of life questionnaire at baseline (T0), after 4 weeks (T1), at the last Osteopathic Manipulative Therapy or Light Touch Therapy (T2), at 3 months from baseline (T3). Results: The study started in April 2018 and we recruited eighteen patients, 15 females and 3 males (mean age: 12.9 years, range 8-17). Seven of these had already completed the study with the last evaluation at T3; for 8 patients the treatments are ongoing and 3 patients interrupted the study due to poor compliance. Conclusions: Several studies have demonstrated the effectiveness of OMTh in high frequency tension-type headache on adults but its role in paediatric headache is unknown. This is the first study conducted in paediatric age that evaluates the possible efficacy of OMTh on high frequency headache. The results are still partial and we need to recruit more patients to have a statistical significance. Background: Post-herpetic neuralgia is difficult to treat and over 50% of patients fail to achieve satisfactory relief from pain, despite the application of the most effective methods of care available. Current guidelines recommend the use of anticonvulsant drugs, antidepressants, topical treatments and opioid drugs, administered individually and in resistant cases in combination. Our clinical case reports the result of the combination of pharmacological and infiltrative therapy in the treatment of post-herpetic neuralgia. Case reports:A 60-year old male appeared complaining of severe pain (RSV 8) in the left occiput-parietal-frontal region which had been occurring for about 5 months. Morning pain of moderate intensity (RSV 5) was accentuated during the day until it became severe in the evening and did not regress with the administration of NSAIDs and opiates (Tramadol) taken at high doses. Speaking with the patient about his clinical history a herpetic-type rash emerged in the same area about 3 years earlier. It was decided to start therapy with Pregabalin 75 mg 2 times/day for 15 days and then 150 mg 2 times/day for 1 month without significant improvement in symptoms (RSV 7). After 2 months of oral drug treatment, it was decided to associate Pregabalin therapy with 1 cycle of 3 ultrasound guided infiltrations (large occipital nerve block) with administration of Lidocaine (80 mg) and dexamethasone (4 mg) spaced 7 days before the first two and 15 days the second from the third. Results: The patient reported temporary improvement (3 days) after the first 2 infiltrations with gradual recovery of painful symptoms. At followup performed after 1 month from the last infiltration the patient reported discreet control of the symptoms (RSV 3-4), this improvement persisted at 3 months from the infiltration despite the reduction of the oral medication (Pregabalin reduced to 75 mg 2 times/day) Conclusions: In our opinion, infiltrative therapy with ultrasound-guided nerve blocks is a valid support in the treatment of pain caused by postherpetic neuralgia, where medical therapy alone does not allow optimal control of symptoms. Discordant results on the efficacy of infiltrative therapy are reported in the literature and standardized infiltration timings have not been proposed; in our opinion the frequency used in this case, 3 infiltrations in 1 month spaced 7 and 15 days respectively, could be applicable in the majority of patients. Background and objectives: Most migraineurs patients need prophylactic treatments to reduce the burden of disease in terms of attacks, days with headache, and symptomatic drugs consumption because their headache is characterized by a middle to high frequency of migraine attacks. So far, pharmacologic prophylactic treatments are characterized by a suboptimal efficacy due to the high number of patients that do not respond to the treatments, and the elevated incidence of side effects. To match the patient needs, waiting for the next generation treatments, the use of herbal medicine is very common among the migraine population. In the last years, phytoextracts of feverfew (tanacetum parthenium) were studied and adopted to treat migraineurs. In particular, there is a fixed combination of Tanacetum Parthenium, Andrographis, Coenzyme Q10, and Riboflavin, that is widely used in Italy. In order to verify the efficacy of that association, we designed a randomized double blind versus placebo clinical trial. Methods: Forty patients were enrolled and randomly assigned to receive the verum or the placebo treatment for 3 months. Each treatment kit, blinded by a unique code that was coupled to each patient, was composed by 120 pills, enough for 3 months: (1 pill b.i.d. in the first month, 1 per day in the second and third month). Results: When the blind was broken, 21 patients resulted to be assigned to verum group, 19 to placebo. Eight patients out of 21 assigned to the verum arm of the study improved their headache frequency at least 50% (responder rate of 38.1%). On the contrary, only 2/19 patients that received the placebo treatment improved their headache frequency at least 50% (responder rate of 10.52%). No major side effects were reported. Conclusions: The traditional use of herbal medicine is as old as the history of medicine and that ancient practice is present in almost all cultures. Our results show that the examined combination is effective in the migraine prophylaxis if compared to placebo and safe if compared with data about synthetic drugs, as they are reported in literature.
A particular case of facial paraesthesias due to a meningioma 2 Outpatient Neurological C l i n i c , P. T. A . BB i o n d o^A .S . P. P al e r mo , I t al y ; e -m a i l : angelotorrente92@gmail.com Background: Meningiomas are the most frequently diagnosed primary brain tumors (about 30% of all primary brain and central nervous system tumors). Although most are benign, their intracranial location may lead to severe and even potentially lethal consequences. Most meningiomas are asymptomatic, some may cause seizures and others may lead to focal signs. Here, we aim to show a particular case of facial paraesthesias due to the uncommon cause of a meningioma. Methods: A 63-year-old woman came to our outpatient neurological clinic for the gradual onset of paraesthesias to the left half of the superior lip in three months. Her complaint started as a tingling sensation and became progressively more and more intense until turning into a burning and swelling sensation. The sensations were constant, worsened by speaking and reduced during the night. We first prescribed a medical therapy (pregabalin and a supplement drug containing vitamins B1, B6, E and α-lipoic acid). After, the patient underwent a massive facial MR and, later, a brain contrast enhanced (CE) MR. Finally, she underwent a neurosurgical and a radiotherapy consultation and cyberknife intervention. Results: Neurological examination was irrelevant, symptoms decreased just a little after medical therapy. The basic massive facial MR showed only an intrasellar arachnoidocele. The following brain CEMR showed an extracranial vascularised formation at the level of left cerebellopontine angle (coronal diameter 13x12mm, axial one 16.7x16.4mm), with marked dural contrast enhancement and associated to compression of the origin of left trigeminal nerve and Gasser's ganglion. Such formation was referable to a meningioma. Neurosurgeon suggested to consult a radiotherapist, who set two options: watchful waiting or performing cyberknife intervention; our patient chose the latter option (25Gy in 5 fractions) with a reduction of symptoms (no more swelling sensation and no speech worsening), but persistence of paraesthesias. Conclusions: Cerebellopontine angle tumors may cause trigeminal neuralgia, but such painful condition is usually brief, intense and electric shock-like. In our case, the meningioma is probably the cause of such particular clinical presentation and cyberknife intervention may have reduced tumor dimensions, soothing symptoms. Since the patient did not recover fully, other approaches are still needed. Background: Kudzu (pueraria lobata) is a wild climbing plant native to Central Asia belonging to the Fabaceae family, with a root having a high content of isoflavones. This open-label observational study evaluated the efficacy and tolerability of kudzu (K) developed with an innovative programmed release technology (Kuzik® by GAM FARMA) in a sample of 60 consecutive patients with migraine without aura (MWOA), who needed prophylaxis treatment (diagnosis and prophylaxis according to ICDH-II) Methods: Sixty patients (F/M = 13/47, age: 37.9±11.4) with MWOA received K at a dose of 1 cps UID for 120 days. The efficacy of the treatment was evaluated considering the days of headache per month (primary endpoint), pain intensity according to the NRS scale and NSAID consumption per month (secondary endpoints), at T0, T1 and T2 (after 60 and 120 days of therapy), with the help of the patient's headache diary. Results: Frequency: At T0, was 10.1±3.2. At T1, the average frequency was 6.8±3.2 (min: 0 max: 15) resulting in a statistically significant mean reduction of 3.3 attacks (I.C. 95%: 2.6 -3.9; p<0.001). At T2 the value was 5.7 ± 2.8 with an average reduction, compared to T0, of 4.4 (95% CI: 3.6 -5.2; p<0.001). The percentage of patients who observed a reduction equal to or greater than 50% in the frequency was 16.7% at T1 and 31.7% at T2. NRS: The mean value on NRS on T0 was 8.3±3.2. At T1, a statistically significant reduction of 2.0 points was observed (I.C. 95% 1.5 -2.5%, p<0.001). At T2, the mean reduction from baseline was 2.7 points (I.C. 95% 2.0 -3.4%, p<0.001). NSAID Consumption: At T0 the average consumption of NSAID was 9.5±4.7 units. At T1 the consumption was reduced by 3.6 units (95% CI: 2.5 -4.7, p<0.001), this reduction was substantially confirmed at T2 (4.5, 95% CI: 3.2 -5.7, p<0.001) with NSAID consumption 5.0±3.1 units. Conclusions: The prophylactic use of Kudzu resulted in a reduction equal to or greater than 50% of the frequency in 31.7% of patients, a significant reduction in the average consumption of NSAID and in the NRS score. No side effects were reported during therapy. These data demonstrate the efficacy of Kudzu as prophylaxis treatment for migraine without aura, associated with good tolerability. Background: Migraine preventive treatment is intended to reduce the frequency, severity, and disability associated with migraine attacks. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved for the preventive treatment of migraine. Methods: In this 52-week, multicenter, randomized, double-blind, parallel-group study, patients with EM (rolled over from a placebocontrolled study and new patients) received either subcutaneous fremanezumab quarterly (675 mg every 3 months) or monthly (225 mg every month). The percentage of patients achieving ≥50% reduction in monthly average number of migraine days or headache days of at least moderate severity, the mean change from baseline in the monthly number of days of use of any acute headache medications, and the mean change from baseline in Migraine Disability Assessment (MIDAS) scores were assessed. Results: This study enrolled 780 patients (119 new, 661 rollover). The proportion achieving ≥50% reduction in migraine days at Month 12 was 66% with quarterly dosing and 68% with monthly dosing. Similar response rates were observed for headache days of at least moderate severity (quarterly 68%, monthly 66%). The mean change in monthly number of days of use of any acute headache medications from baseline to Month 12 in patients with EM was -4.6 days in the quarterly group and -4.4 days in the monthly group. The change from baseline in the MIDAS disability score in patients with EM was similar in both treatment groups at Month 12; disability scores decreased by 26.0 and 27.4, respectively, in the quarterly and monthly groups. Conclusions: Efficacy, reduced acute medication use, and improvements in disability were maintained through 12 months of treatment with fremanezumab in patients with EM.
Efficacy of fremanezumab in patients with
High frequency migraine with aura: efficacy of combination of tanacetum parthenium, 5-HTP and Mg+ (Aurastop©) in the reduction of the frequency of the aura attacks Background: Each component of the novel phytotherapic combination of Tanacetum Parthenium (150 mg), 5-hydroxy tryptophan (20 mg) and magnesium (185 mg) (Aurastop©) acts on a different target among the main mechanisms involved in the pathophysiology of migraine and of the aura itself: sensitization of the trigeminal vascular system, central sensitization and activation of the "migraine generator" located in the brainstem, through glutammate and kynurenine pathways and the cortical spreading depression. Aim of this study was to test the effectiveness of Aurastop© in the prophylaxis of migraine with aura with high frequency Methods: Thirty patients (F: n=18, M: n=12, mean age: 32) presenting with an ICHD-3 beta diagnosis of migraine with aura (MWA) but with a frequency of more than 5 attacks of migraine with aura per month for at least 6 months, (High frequency MWA) were enrolled in the survey and treated with Aurastop© twice a day for a period of 3 months. Diary cards were filled in during a 3-months period prior the beginning of the survey and during the 3-months duration of the study. The reduction of MWA attacks per month was assessed as the primary end-point; the reduction of the duration and disability of the aura and of the intensity of the headache were considered as secondary end-points. Results: A statistically significant reduction of MWA attacks/month was observed: more than 90% of the patients referred a reduction >60% of the frequency. Moreover, a sensible reduction of the duration and disability of the aura phenomena was reported by more than 80% of the patients and, in 55% of the patients also a reduction of the intensity of the headache. No side effects were reported. The efficacy started to appear during the first month of intake and was maintained during the three months of therapy .
Conclusions:
In this observational open study, Aurastop© appears to be effective and safe as a preventive treatment of MWA in the patients with a high frequency of attacks.
Comparison of the effect of tanacetum parthenium, 5-hydroxy tryptophan and Mg+ (Aurastop) versus magnesium alone on aura phenomenon and its evolution L. Savi ) with at least 3 episodes of aura per year were included (t0). Participants were instructed to keep track of the following 4 episodes of migraine with aura (t1), and invited to assume 1) a tablet of Aurastop at the beginning of the following 2 episodes of aura, and 2) a magnesium tablet alone at the occurrence of the third and fourth aura attacks. Results: Forty-eight (96.0%) had >50% reduction in aura duration when treated with Aurastop vs 7 (14.0%) when treated with magnesium alone (p<0.001), 48 (96.0%) had >50% reduction of aura-related disability when receiving Aurastop vs 5 (10.0%) patients when treated with magnesium alone (p<0.001), while patients receiving Aurastop did not need to take pain killers in 35% of aura attacks vs 3% when assuming magnesium (p<0.001). Conclusions: These results support the hypothesis that Aurastop might be effective in interfering with the phenomenon of aura and provide evidence that the clinical benefit attributable to this combination of molecules might be greater than that obtained with single compounds of proven effect on the biology of migraine. Background: Chronic migraine is a neurological condition with a high disease burden and unmet clinical need. The objective was to assess longterm efficacy and safety of galcanezumab, a humanized monoclonal antibody that selectively binds to calcitonin gene-related peptide, in adult patients with chronic migraine. Methods: This was a phase 3, double-blind (DB), randomized, placebocontrolled, 3-month study with a 9-month open-label extension (OLE). Eligible patients with chronic migraine were randomized 2:1:1 to subcutaneous injections of placebo (N=558), galcanezumab 120mg with a 240 mg loading dose (N=278), or galcanezumab 240 mg (N=277), given once monthly for 3 months. Patients entering the OLE received a 240-mg loading dose of galcanezumab, followed by a maintenance dose of 120mg/month at the next month, with flexible dosing thereafter (120 or 240 mg/month). Efficacy measures included number of monthly migraine headache days (MHD), ≥50% reduction in monthly MHD, and MigraineSpecific Quality of Life Questionnaire Role Function-Restrictive (MSQ-RFR) domain score. Change from baseline in continuous and categorical measures over 12 months was analyzed using mixed model repeated measures analysis and generalized linear mixed models (GLIMMIX), respectively. OLE results are reported by prior DB treatment assignment. Results: Of 1,037 patients who completed DB treatment, 1,022 subsequently entered the OLE, with 825 completing. Patients previously treated with placebo showed a rapid mean reduction in monthly MHDs after the first open-label dose and maintained this improvement over time, whereas the previous 120 and 240mg galcanezumab groups generally maintained or improved upon gains from the DB treatment phase (month 12: placebo, -8.41; galcanezumab 120mg, -8.89; galcanezumab 240mg, -7.99 from a baseline of 19.4 MHDs). The mean percentage of patients with ≥50% reduction from baseline ranged 44.5-45.6% at month 6 and 53.3-56.9% at month 12. Mean improvement from baseline on MSQ RF-R ranged 26.5-30.2 points at month 6 and 29.0-32.9 points at month 12 on the 100-point scale. The most common (≥5%) treatment-emergent adverse events were nasopharyngitis (9.6%), upper respiratory tract infection (6.2%), and injection-site reaction (5.9%). 4.5% of patients discontinued due to an adverse event, and 4 patients (0.4%) discontinued due to an injection-site-related adverse event. There were no clinically meaningful changes in any of the safety measures. Conclusions: Final OLE results support the observation that galcanezumab appears effective, safe, and well tolerated for the preventive treatment of chronic migraine. Galcanezumab had a favorable safety profile after 1 year of treatment at doses of 120 or 240mg/month. No new safety findings were identified.
Shift from chronic migraine to episodic migraine status in a longterm phase 3 study of galcanezumab Background: Relative to episodic migraine, chronic migraine is associated with substantially greater disease-state burden due to higher rates of disability, comorbid conditions, acute medication use and healthcare resource utilization. Galcanezumab is approved for prevention of chronic and episodic migraine. Results from a long-term Phase 3 study in patients with chronic migraine are reported. The objective was to assess proportions of patients with chronic migraine who shift to episodic migraine status during treatment with galcanezumab or placebo. Methods: REGAIN included patients aged 18-65 years with an ICHD-3β diagnosis of chronic migraine who met chronic criteria during a 1-month prospective baseline period (i.e. ≥15 headache days/month, of which at least 8 are migraine headache days [MHDs] ). Patients were randomized 2:1:1 to receive subcutaneous monthly injections of placebo, galcanezumab 120 mg (with a loading dose of 240 mg) or galcanezumab 240 mg for up to 3 months of double-blind treatment. Patients who completed the double-blind period could enter a 9-month open-label extension (120 or 240 mg/mo galcanezumab). Results from patients who received galcanezumab during the double-blind and/or open-label periods are reported. Achieving episodic migraine status was defined as <8 MHDs or <15 headache days/month for ≥3 consecutive months. In addition, we evaluated the proportions of patients who shifted to <8 MHDs/month (low frequency) and <4 MHDs/month (very low frequency). Results: In REGAIN, at baseline, mean (SD) number of MHDs/month was 19.4 (4.5) and mean (SD) number of headache days/month was 21.4 (4.1). At the end of double-blind treatment period (Month 3), a greater proportion of galcanezumab-treated patients shifted to episodic status (30.9%) than did placebo-treated patients (19.7%). Among galcanezumab-treated patients across the entire 12-month trial, 65.1% shifted from chronic migraine to episodic status, 44.2% shifted to low frequency and 21.5% shifted to very low frequency for ≥3 consecutive months. Proportions of patients shifting from chronic migraine to episodic status for ≥3 consecutive months and until last patient visit were: shift to episodic status: 55.0%; shift to low frequency: 33.4%; shift to very low frequency: 13.9%. Conclusions: Treatment with galcanezumab led to a majority of patients with chronic migraine shifting to episodic migraine status. These results suggest that long-term treatment with galcanezumab may lead to substantial reductions in the disability and economic burden associated with chronic migraine. Background: The Migraine Disability Assessment (MIDAS) and the Migraine-Specific Quality of Life Questionnaire v.2.1 (MSQ) are patient-reported outcome instruments that assess patients' migrainerelated disability and functional impairment. The objective of this study was to evaluate categorical shifts in patients' migraine-related disability and functioning after treatment with galcanezumab. Methods: The MIDAS and MSQ were performed during three doubleblind clinical studies, including two 6-month studies that enrolled patients with episodic migraine (EVOLVE-1 and EVOLVE-2, N=1,773) and one 3-month study of patients with chronic migraine (REGAIN, N=1,113 ). Based on MIDAS scores, patients were grouped into 5 disability grades, from Blittle/no disability^up to Bvery severe disability.^Categorical shifts in MIDAS disability grade from baseline to endpoint were compared between galcanezumab and placebo groups. Individual improvements in the 7 items of the MSQ Role Function-Restrictive domain (MSQ-RR) were also evaluated. Results: Among patients who had Bmoderate to very severe disability^at baseline in EVOLVE-1&2 (pooled), 44.0% of galcanezumab patients shifted to Blittle/no disability^at the end of 6 months, compared to 26.5% of placebo patients. Among patients with Bvery severe disabilityâ t baseline in REGAIN, 49.5% of galcanezumab patients had shifted to lower grade levels at the end of 3 months, compared to 39.9% of placebo patients. Patients using galcanezumab improved their MIDAS disability grade by one or more grades at study completion at significantly (p<0.01) higher rates than were seen with placebo (73.0% vs 57.5% for episodic and 48.6% vs 40.3% for chronic). Significantly (p<0.001) greater percentages of patients showed improvements in each MSQ-RR item for EVOLVE-1&2 when treated with galcanezumab (range: 73.1% to 80.3%) compared to placebo (range: 60.4% to 66.1%); REGAIN results were also significant for most items.
Conclusions: Patients treated with galcanezumab for the prevention of episodic or chronic migraine showed lower levels of migraine-related disability and greater improvements in daily functioning compared to placebo.
Rapid onset of effect of galcanezumab for the prevention of episodic migraine: post-hoc analyses of two phase 3 studies Eli Lilly SpA, Roma, Italy; e-mail: antenori_amalia@lilly.com Background: The humanized monoclonal antibody galcanezumab (LY2951742), which binds to calcitonin gene-related peptide, has been evaluated for migraine prevention. The aim of these post-hoc analyses is to describe the onset of effect of galcanezumab for prevention of episodic migraine based on data from the Phase 3 clinical program. Methods: These analyses were derived from patients who participated in the randomized, double-blind, placebo-controlled Phase 3 studies (EVOLVE-1 [NCT02614183] and EVOLVE-2 [NCT02614196]) that included patients aged 18-65 years with a diagnosis of episodic migraine and a history of migraine headaches for ≥1 year. A total of 1,773 (858 EVOLVE-1, 915 EVOLVE-2) patients were randomized and received either 120 mg or 240 mg galcanezumab (n=879) or placebo (n=894). Study drug was administered subcutaneously once per month for 6 months. The patient population was predominately female (83.7% EVOLVE-1, 85.4% EVOLVE-2) and white (80.4% EVOLVE-1, 70.3% EVOLVE-2) with a mean age of approximately 41 years (40.7 years EVOLVE-1, 41.9 years EVOLVE-2). On average, patients had been diagnosed with migraine approximately 20 years prior to study entry (20.1 years EVOLVE-1, 20.6 years EVOLVE-2), most patients experienced severe disability (Migraine Disability Assessment total score: 33.2 EVOLVE-1, 33.0 EVOLVE-2); the approximate mean number of baseline monthly migraine headache days (MHDs) was 9 (9.1 days EVOLVE-1 9.1 days EVOLVE-2). Patients in the 120-mg group received a 240-mg loading dose for the first month. Onset-of-effect analyses therefore evaluated the pooled galcanezumab-treated patients vs placebo as both galcanezumab groups received 240 mg in the first month. The number of weekly MHDs was modeled using a repeated measures ordinal logistic regression, and the odds ratios of having fewer MHDs for the galcanezumab group compared with the placebo group were evaluated for each week in Month 1. Onset of effect was defined as the earliest week in which a statistically significant separation between galcanezumab and placebo was observed and maintained for all remaining weeks in Month 1. Results: For both studies, change from baseline in MHD showed a statistically significant separation of galcanezumab from placebo at Month 1 and for all subsequent months (each p<0.001). The weekly MHD analyses showed that onset of effect occurred at Week 1. The odds ratio of having fewer weekly MHDs with galcanezumab vs placebo was statistically significant at Week 1 for each study and maintained for Weeks 2-4 (p≤0.004). Conclusions: This rapid onset of effect of galcanezumab makes it a promising medication for prevention of migraine.
Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment Background: CM and EM are clinically, functionally, and anatomically differentiated, with evidence suggesting that they may be separate conditions. Furthermore, patients with CM usually have more comorbid conditions and more-frequent medication overuse, which complicates their clinical management. Fremanezumab (TEV-48125), a fully humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), has demonstrated efficacy in migraine prevention. Methods: In this Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, adults with prospectively confirmed CM (≥15 headache days and ≥8 migraine days per month) were randomized 1:1:1 to subcutaneous injections of fremanezumab quarterly (675 mg at baseline; placebo at Weeks 4 and 8), fremanezumab monthly (675 mg at baseline; 225 mg at Weeks 4 and 8), or matching placebo over a 12-week treatment period. Post hoc analyses evaluated the proportion of patients who reverted from CM to EM, defined as patients who had ≥15 headache days per month at baseline (28-day pre-treatment period) and then had <15 headache days per month in all 3 months of the treatment period.
Results: In an analysis of the 1130 CM patients randomized in this trial (quarterly, N=376; monthly, N=379; placebo, N=375), significantly more fremanezumab-treated patients reverted from having ≥15 headache days per month at baseline to <15 headache days per month in Months 1, 2, and 3 (quarterly: 121 patients [32%] ; monthly: 133 patients [35%]) than those who received placebo (86 patients [23%]; both, P≤0.002). On average, these fremanezumab-treated patients had 18-19 headache days per month at baseline and showed reductions to 6-9 headache days during any month in the treatment period, representing up to an approximately 70% reduction in headache days. Conclusions: Along with its efficacy as a migraine preventive treatment, fremanezumab demonstrated the potential benefit for reversion from CM to EM.
The impact of fremanezumab on headache-related disability in patients with chronic migraine using the Headache Impact Test (HIT-6) Background: Fremanezumab is a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), has been shown in clinical trials to reduce the frequency, severity, and duration of headaches in patients with chronic migraine (CM). However, the full impact of a treatment cannot be fully evaluated from headache frequency alone. Accordingly, the 6-item Headache Impact Test (HIT-6) has been developed to assess headache-related disability. Methods: Study TV48125-CNS-30049 was a 12-week multicenter, double-blind study of the efficacy, safety, and tolerability of fremanezumab in treatment of CM. Eligible patients were randomly assigned 1:1:1 to quarterly dosing (fremanezumab 675 mg s.c. at baseline, placebo at Weeks 4 and 8), monthly dosing (fremanezumab 675 mg at baseline, 225 mg at Weeks 4 and 8), or placebo at each time point. As a secondary endpoint, HIT-6 scores were evaluated from baseline to 4 weeks after the last dose. Efficacy analyses were performed in the full analysis set (FAS; all randomized patients receiving ≥1 dose and having ≥10 days of post-baseline primary endpoint assessments, N=1121), and repeated for the per-protocol analysis set (PPS; all patients completing the study without violation of eligibility criteria or omission of drug administration, N=959). Results: Treatment with both fremanezumab regimens led to significant and large reductions in HIT-6 scores from baseline to endpoint. In the FAS, least-squares mean changes (± standard error) were −6.4±0.5 for quarterly dosing (n=375), −6.8±0.4 for monthly dosing (n=375), and −4.5 ±0. 5 for placebo (n=371), leading to significant treatment differences (quarterly: −1.9±0.5; monthly: −2.4±0.5; both P<.001). Similar treatment differences were observed in the PPS (quarterly: −2.1±0.5; monthly: −2.3 ±0.5; both P<.001). Conclusions: In this Phase 3 study, fremanezumab treatment was associated with significant improvement in headache-related disability in patients with CM.
The impact of fremanezumab on headache-related disability in patients with episodic migraine using the Migraine Disability Assessment Background: Episodic migraine(EM), attacks on ≤15 days per month, has a risk for progression to chronic migraine and affects daily functioning. In clinical trials, fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa), selectively targets calcitonin gene-related peptide ligand, reduced headache frequency in EM patients. The impact of migraine is evaluated utilizing the Migraine Disability Assessment (MIDAS), a validated questionnaire, to assess disability in migraine patients. Methods: 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in adults with EM(TV48125-CNS-30050), randomized 1:1:1 ratio to 1 of 3 treatment groups: (1)monthly dosing: 225 mg fremanezumab at months 1, 2 and 3, (2)quarterly dosing: 675 mg fremanezumab at month 1, followed by placebo injections at months 2 and 3, and (3)monthly administration of matching placebo. As a secondary endpoint, changes in MIDAS scores were evaluated from baseline to 4 weeks after last dose. Efficacy analyses were performed in the full analysis set (FAS; all randomized patients receiving ≥1 dose and having ≥10 days of post-baseline primary endpoint assessments, N= 865), and repeated for the per-protocol analysis set (PPS; all patients completing the study without violation of eligibility criteria or omission of drug administration, N=847). Results: A total of 875 patients were randomly assigned to fremanezumab quarterly (n=291), fremanezumab monthly (n=290), or placebo (n=294). Least square mean (± standard error) changes from baseline in MIDAS score were larger for fremanezumab (quarterly:−23.0±1.6; monthly: −24.6±1.6) than for placebo (−17.5±1.6), resulting in significant treatment differences (quarterly: −5.4±1.8, P=.002; monthly: −7.0±1.8, P<.001) versus placebo. Similar treatment differences versus placebo were observed in the PPS (quarterly: −5.5±1.9, P=.003; monthly: −7.3±1.8 points, P<.001). Conclusions: In this Phase 3 study, fremanezumab treatment demonstrated a significant improvement in headache-related disability in patients with EM. Background: Overuse of acute or symptomatic headache medications, such as triptans, ergot derivatives, opioids, and combination analgesics, can cause medication overuse headache (MOH). CM is often accompanied by MOH. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is efficacious in preventing CM. Methods: In this Phase 3, multicenter, randomized, double-blind, placebo-controlled study, CM patients were randomized 1:1:1 to receive subcutaneous fremanezumab quarterly (675 mg at baseline, and placebo at Weeks 4 and 8), fremanezumab monthly (675 mg at baseline, and 225 mg at Weeks 4 and 8), or placebo (at baseline, Weeks 4 and 8). We assessed the proportion of patients who reverted from overusing medications at baseline to not overusing medications during the 12-week treatment period, and the change from baseline in the number of days of acute headache medication use. Results: Among patients with medication overuse at baseline (quarterly n=201; monthly n=198; placebo n=188), more patients treated with fremanezumab reported no medication overuse during the treatment period (quarterly: 55%, P=0.0389; monthly: 61%, P=0.0024) than those who received placebo (46%). Response to treatment was seen by Week 4 (quarterly: 51%, P=0.0091; monthly: 54%, P=0.0014; vs placebo: 39%). Among the patients who responded to treatment, the baseline number of days with medication overuse was similar across treatment groups (quarterly [mean]: 16.6 days; monthly: 16.7 days; placebo: 16.6) . Within this population, fremanezumab treatment significantly reduced the days of acute headache medication use (quarterly: -9.0 days, P=0.0017; monthly: -8.9 days, P=0.0040) compared with those who received placebo (-7.1 days). Conclusions: Fremanezumab treatment was associated with a reduction in overuse of acute medications and a corresponding decrease in days using acute medications.
Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with chronic migraine: Results of a one-year study Background: Migraine preventive treatment is intended to reduce the frequency, severity, and disability of migraine attacks. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved in the US for the preventive treatment of migraine.
Methods: In this 52-week, multicenter, randomized, double-blind, parallel-group study, patients with CM received either subcutaneous fremanezumab monthly (225 mg every month with a starting dose of 675 mg) or quarterly (675 mg every 3 months). The percentage of patients achieving ≥50% reduction in monthly average number of headache days of at least moderate severity or migraine days, the mean change from baseline in the monthly number of days of use of any acute headache medications, and the mean change from baseline in Headache Impact Test (HIT-6) score (assessing disability) were assessed. Results: This study enrolled 1110 patients with CM. The proportion achieving ≥50% reduction in monthly average number of headache days of at least moderate severity at Month 12 was 54% with quarterly dosing and 59% with monthly dosing. The proportion achieving ≥50% reduction in monthly average number of migraine days at Month 12 was 53% with quarterly dosing and 57% with monthly dosing. The mean change in monthly number of days of use of any acute headache medications from baseline to Month 12 was -6.0 days in the quarterly group and -6.2 days in the monthly treatment group. HIT-6 scores decreased by 8.4 and 7.7 at the end of treatment for the monthly and quarterly groups, respectively, meeting the minimally important difference. Conclusions: Efficacy, decreased acute medication use, and improvements in disability were maintained through 12 months of treatment with fremanezumab in patients with CM. Background: Overuse of acute headache medications in people with EM can lead to worsening of headaches or transformation to chronic migraine. Fremanezumab (TEV-48125), a fully humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), has proven efficacy in migraine prevention. Methods: In this Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, eligible adult patients with prospectively confirmed EM (6-14 headache days and ≥4 migraine days per month) were randomized 1:1:1 to receive subcutaneous injections of fremanezumab monthly (225 mg at baseline, Weeks 4 and 8), fremanezumab quarterly (675 mg at baseline, and placebo at Weeks 4 and 8), or placebo at each time point over a 12-week treatment period. The monthly numbers of days on which patients used either acute headache medications of any type or those specific to migraine (triptans and ergots) were evaluated as secondary and exploratory endpoints. Results: 875 patients were randomized (monthly, N=290; quarterly, N=291; placebo, N=294). Both fremanezumab regimens significantly reduced the monthly number of days with use of any acute medication (monthly: −3.0±0.22 days; quarterly: −2.9±0.22 days;) versus placebo (−1.6±0.21 days) during the 12-week treatment period (both, P<0.0001), with significant reductions observed as early as Week 4 (monthly: −2.9±0.24 days; quarterly: −2.8±0.24 days; placebo: −1.1±0.24 days) and at each time point thereafter (all, P<0.01). Similarly, fremanezumab significantly reduced migraine-specific acute headache medication use (monthly: −3.1 ±0.26 days; quarterly: −3.1±0.26 days) versus placebo (−0.9 ±0.27 days) over the 12-week period (both, P<0.0001). Conclusions: Fremanezumab reduces the need for acute headache and migraine-specific medication use in patients with EM. Background: Alcoholic beverages cause in susceptible individuals headaches associated with flushing and hangover and provoke migraine attacks in a relevant proportion of migraineurs. A typical feature of alcoholevoked headaches is a delayed onset that markedly outlasts the presence of ethanol in blood and tissues. The transient receptor potential vanilloid 1 (TRPV1) that belongs to the TRP family of ion channels, is selectively gated by 1-3% concentrations of ethanol, that by this mechanism signals pain and inflammation. Another TRP channel, the ankyrin 1 (TRPA1) subtype, highly sensitive to the redox state of the milieu, is gated by an unprecedented series of reactive oxygen (ROS), nitrogen (RNS) and carbonyl (RCS) species and unsaturated and saturate aldehydes, including the ethanol metabolite, acetaldehyde. The present study explored the role of TRP channels in mediating prolonged responses that may be relevant for the delayed ethanol-evoked headaches in patients. Methods: Ethanol and acetaldehyde were administered by local injection in the periorbital area of C57BL/6, and TRPA1 and TRPV1 wild type and knock out mice. Spontaneous nociception was assessed by measuring the time (seconds) that the animal spent face rubbing the injected area with its paws. Periorbital mechanical allodynia was evaluated by applying the von Frey filaments to the periorbital region over the rostral portion of the eye before and after (1-24 h) ethanol or acetaldehyde. Antagonists were administered by local and systemic injections. Results: Local injection of ethanol in the periorbital skin caused two sensory responses, which are temporally and mechanistically distinct: a short-lived nociceptive response that was absent and a delayed and prolonged mechanical allodynia that was maintained in TRPV1-deleted mice. Allodynia was prevented by pretreatment with an alcohol dehydrogenase inhibitor, thus supporting the view that acetaldehyde, derived from ethanol metabolism, mediates the prolonged allodynic effect of ethanol. In addition, genetic deletion of TRPA1 prevented ethanol-and acetaldehyde-evoked allodynia underling that the aldehyde and not its precursor gates TRPA1 and plays a major role in the ethanol-evoked allodynia.
Conclusions: The present study confirms that exposure to ethanol causes an acute nociceptive response that is mediated by TRPV1 and reveals that the prolonged mechanical allodynia is due to TRPA1 activation by the alcohol metabolite, acetaldehyde. Results underline that TRPA1 may be an effective molecular target for an effective treatment for pain caused by alcohol ingestion.
Ethanol ingestion causes prolonged pain in mice via Schwann Cells and TRPA1
D. Souza Monteiro De Araujo
Background: Alcohol abuse and dependence are among the major healthcare problems in the world and around 60% of alcoholics exhibit neuropathic pain. Alcohol dehydrogenase (ADH) converts ethanol into the reactive and toxic product acetaldehyde, which is rapidly metabolized to acetic acid by the mitochondrial aldehyde dehydrogenase-2 (ALDH2). Acetaldehyde is considered as the major contributor of the detrimental effects produced by acute and chronic alcohol consumption, including flushing, headache, cirrhosis and cancer. The transient receptor potential ankyrin 1 (TRPA1) channel, a sensor for oxidative and carbonyl stress, can be activated by acetaldehyde generated by alcohol dehydrogenase (ADH) in the liver and other tissues. However, the pathways by which acetaldehyde causes ethanol-evoked pain are poorly understood. Methods: Periorbital mechanical allodynia was assessed with the von Frey filaments after acute and chronic ethanol ingestion (intragastric administration) in C57BL/6 and in mice with TRPA1 genetic deletion. The presence of ADH was assessed in neuronal tissue and Schwann cells by immunofluorescence. The content of by-products of oxidative stress (H 2 O 2 and 4-hydroxynonenal, 4-HNE) was determined by immunofluorescence and colorimetric assay. Results: Both acute and chronic ethanol ingestion caused delayed periorbital mechanical allodynia in mice. Inhibition of ADH or deletion of TRPA1prevented allodynia. Acetaldehyde generated by ADH in both liver and Schwann cells surrounding nociceptors was required for TRPA1-induced allodynia. Schwann cell-(Plp1-Cre;Trpa1 fl/fl ) specific deletion of TRPA1 revealed that channel activation by acetaldehyde results in NADPH oxidase-1 (NOX-1)-dependent production of H 2 O 2 and 4-HNE, which sustain allodynia by paracrine targeting of nociceptor TRPA1. Human Schwann cells express ADH/TRPA1/NOX1 and recapitulate the proalgesic functions of mouse Schwann cells. Conclusions: The presence of ADH in Schwann cells that express TRPA1/ NOX1 and their ability of generating oxidative stress identifies an autocrine pathway that we propose as a major contributing mechanism in alcoholevoked mechanical allodynia. These findings suggest that antagonists of TRPA1 might represent a therapeutic options for ethanol-evoked pain in humans.
Mouse model of migraine induced by proinflammatory agents Background: Administration of endogenous mediators or exogenous chemicals in migraine patients provokes early headaches and delayed migraine-like attacks. Despite breakthroughs in our understanding of the pathogenesis of migraine and in the development of treatment options, considerable gaps remain in our knowledge of the signalling pathways involved, and specific biomarkers of migraine are lacking. Sustained mechanical allodynia is a common response associated with the local administration of various proalgesic substances in experimental animals and humans. Here, we investigated the ability of a series of endogenous autacoids which have been implicated in migraine mechanism to provoke or do not provoke mechanical allodynia upon their injection in the mouse periorbital area. Methods: Different stimuli were given by subcutaneous injection in the periorbital area of C57BL/6J mice. Spontaneous nociceptive behaviour was assessed by measuring the time that animals spent face rubbing the injected area with their paws after local administration of prostaglandin E 2 (PGE 2 ), prostacyclin (PGI 2 ) and prostaglandin F 2α (PGF 2α ) and histamine. Mechanical allodynia in the periorbital area was assessed with the von Frey filament assay. Different antagonists were given by local and systemic administration.
Results: Local (periorbital) injection of PGE 2 , PGI 2 , PGF 2α, but not histamine evoked spontaneous nociception. Histamine, PGE 2 and PGI 2 , but not PGF 2α evoked a dose-dependent periorbital mechanical allodynia. The painful responses were attenuated by systemic or local (periorbital) administration of selective antagonists of the histamine (H 1 ), PGE 2 (EP 4 ), and PGI 2 (IP) receptors, respectively. Conclusions: The ability of histamine, PGE 2 , PGI 2 to provoke migrainelike attacks in patients and periorbital allodynia in mice suggests that the study of allodynia in mice may provide information on the proalgesic mechanisms of migraine-provoking agents in humans. Failure of PGF 2α to elicit PMA in mice is consistent with the observation that such prostanoid does not provoke migraine-like attacks in humans.
Cannabis for the treatment of refractory headaches: a case-series of 18 patients Introduction: Cannabinoids are emerging as promising therapies for chronic pain conditions. In Italy, cannabinoids have been recently approved for the treatment of chronic neuropathic pain of moderate or severe intensity (NRS>=7). Since 2017 even general practitioners can prescribe cannabis preparations to their patients. So that, the availability of these drugs has dramatically increased. However, limited evidence exists regarding the use of cannabinoids in chronic migraine. The aim of this study was to assess the possible benefits of its use on chronic migraineurs. Methods: Clinical status of patients receiving cannabis oil formulation named BFM2^(titrated at the 5-8% of delta-9-tetrahydrocannabinol and at 7-12% of cannabidiol) was retrospectively analyzed, to check out variations in headache index, analgesic consumption and medium numeric rating scale (NRS) score. Statistical calculation were made with STATA Ic13 software. Results: Globally, 18 patients were analyzed. Medium age was 53±6. The mean number of headache days over 30 days in the last three months before starting medical cannabis was 0. (ttest P-value=0.0013 ). The most frequent complained adverse events were drowsiness and short attention. Conclusions: Cannabinoid oral formulation can be a safe and effective therapeutic weapon to reduce, at least, pain intensity in chronic refractory headache-helping patients to improve their almost low quality of life.
The acyl-glucuronide metabolite of ibuprofen has analgesic and antiinflammatory effects via the TRPA1 channel Background: Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) that has an analgesic and anti-inflammatory action. Ibuprofen is indicated to relieve inflammation and several types of pain, including headache, muscular pain, toothache, backache, and dysmenorrhea. Therapeutic effects of ibuprofen are attributed to inhibition of prostanoid synthesis by a non-selective, reversible inhibition of both cyclooxygenase 1 (COX1) and 2 (COX2). The transient receptor potential ankyrin 1 (TRPA1) channel, expressed primarily in nociceptors, mediates the action of proalgesic and inflammatory agents also produces during migraine/headache attacks. The metabolism of ibuprofen produces the reactive compound, ibuprofen-acyl glucuronide, which, like other TRPA1 ligands, interacts covalently with macromolecules. We investigated the ability of ibuprofen-acyl glucuronide to antagonize TRPA1 activation and, via this mechanism, its contribution in the analgesic and anti-inflammatory actions of ibuprofen. Methods: To test the ability of ibuprofen-acyl glucuronide to interact with the TRPA1 channel, we used in vitro tools (TRPA1-expressing human and rodent cells and molecular modeling) and to explore its analgesic and anti-inflammatory actions we used in vivo mouse models of inflammatory pain (carrageenan and formalin test). Results: Ibuprofen-acyl glucuronide, but not ibuprofen, inhibited calcium responses evoked by reactive TRPA1 agonists, including allyl isothiocyanate (AITC), in cells expressing the recombinant and native human channel and in cultured rat primary sensory neurons. In addition, molecular modeling studies suggested the key cysteine residue C621 as a probable alkylation site of TRPA1 channels for ibuprofen-acyl glucuronide. Local administration of ibuprofen-acyl glucuronide, but not ibuprofen, in the mouse hind paw attenuated nociception by AITC and other TRPA1 agonists (acrolein and hydrogen peroxide) and the early nociceptive response (phase I) to formalin. Systemic ibuprofen-acyl glucuronide and ibuprofen, but not indomethacin, reduced phase I of the formalin response. Carrageenan-evoked allodynia in mice was reduced by local ibuprofen-acyl glucuronide, but not by ibuprofen, whereas both drugs attenuated PGE 2 levels. Conclusions: The reactive ibuprofen metabolite by blocking TRPA1, suggests that this novel action of ibuprofen-acyl glucuronide might contribute to the analgesic and anti-inflammatory activities of the parent drug. Background: Palmitoyl ethanolamide (PEA) is an amide of endogenous fatty acids widely distributed in different tissues, including nervous tissues. PEA is emerging as a new therapeutic approach in pain and inflammatory conditions and it has been evaluated in studies on various painful diseases. However, to date no studies have been conducted to evaluate the role of PEA in the management of migraine in pediatric patients. The aim of this open-label study was to evaluate the efficacy of ultramicronized PEA (um-PEA) in the prophylactic treatment of migraine. Methods: The study included 53 patients with mean age of 10.67± .1 (24.5% M and 75.5% F). All patients had a diagnosis of migraine without aura (ICHD 3 criteria) and received umPEA (600 mg/day orally) for three months. We compared the attack frequency (AF) and attack intensity at baseline and after three months. Patients were asked to classify the intensity of the attack with a value ranging from 1 to 3 where 1 means mild attack, 2 moderate and 3 severe attack. Results: After 3 months of treatment with um-PEA, the headache frequency was reduced by >50% per month in 56.6% patients. Three patients discontinued treatment too early (less than a month) and were not considered in the results. After three months of treatment the number of monthly attacks decreased significantly compared to the start of therapy (from 13.89±7.6 SD to 6.43±5.1 SD; p<0.05). The intensity of the attacks went from 1.70±0.6 (pre-PEA) to . Discussion: Our preliminary data show that um-PEA administered for three month reduces pain intensity and the number of attacks per month in pediatric patients with migraine. Although the small number of patients and the lack of a control group do not allow us to consider these initial results as definitely reliable, they encourage us to expand the sample.
Comparative assessment of efficacy of physical therapy and onabolulinumtoxin A on headache parameters and pressure pain threshold in chronic migraine M. Deodato, A. Granato, M. Ceschin, P. Manganotti Dipartimento di Scienze Mediche e chirurgiche della salute, Università degli studi di Trieste, Trieste, Italy; e-mail: mdeodato@units.it
Objectives:
The first aim consists to compare Onabotulinum toxin A (BoNT-A) and Physical Therapy (PT) in Chronic Migraine (CM) concerning headache parameters, such as, frequency of migraine, duration of attacks and intensity of pain. The second one of evaluating central sensitization with the instrumental assessment of Pressure Pain Threshold (PPT) in 5 muscles of trigeminal area, 1 far from this area. Methods: Patients suffering from Chronic Migraine (ICHD-3 beta criteria) were enrolled in the Headache Centre of Trieste (T0). Patients were not taking prophylaxis in the three months prior to their enrolment. A three-month baseline period was registered with an ad hoc diary (T1). The PPT was assessed with algometry Somedic in 5 muscles of trigeminal area (trapezius, levator scapula, temporalis, suboccipitalis, middle scalene right and left) and 1 far from this area (tensor fascia lata right and left). The patients followed a randomization scheme 1:1:1 and were included in the 3 treatment groups, respectively (T2): Onabotulinum toxin A (BoNT-A), Onabotulinum toxin A + Physiotherapy (BoNT-A+ PT), Physiotherapy (PT). Finally, after three months of treatment, the final visit was performed (T3) with analysis of the parameters reported in the diary and of the PPT with algometry. Concerning BoNT-A we used a specific protocol PREEMPT approved by FAD, while PT protocol was an integrated type treatment of manual therapy, active exercises and patient education. Data was analysed with Wilcoxon test of the sample pair to compare initial and final evaluations, and Kruskal-Wallis test for the comparison of the two final evaluations. The statistical significance level was 95% (0.05). Results: Six BoNT-A, 10 BoNT-A+PT, 10 PT patients were enrolled. At the final assessment frequency improved statistically significant in all groups (PT p=0.002; BoNT-A+PT p=0.01; BoNT-A p=0.03) and also duration of attacks (PT p=0.009; BoNT-A+PT p=0.002; BoNT-A p=0.03); while pain intensity decreased statistically significant only in BoNT-A (p=0.03) and BoNT-A+PT (p=0.003). Concerning PPT in BoNT-A+PT increased in all muscles and statistically significant in 5 of 12 sites (levator scapula left p=0.02; suboccipitalis left 0.03; middle scalene right p=0.03 and left p=0.01; tensor fascia lata left p=0.01); while in PT in 2 sites (suboccipitalis right p=0.003; tensor fascia lata right 0.04) and in BoNT-A only in one site (suboccipitalis right p=0.03). Conclusions: PT in combination with BoNT-A could be an effective option offered in patients with CM. The combined treatment is more effective in central sensitization than monotherapy treatment with BoNT-A or PT alone. simultaneously with upload of new resources. The items that most capture the attention are PowerPoint presentations and resources closely related to common clinical cases or with short reading time. In each year the activity of the members during the summer appeared to be considerably reduced in number of downloads, uploads and new contributions. Conclusions: The increase in subscriptions shows that our social network dedicated to headaches is appreciated by the scientific community. Nevertheless, the activity does not appear equally increased and a considerable number of members very rarely access the platform. Furthermore, on average the number of uploads is remarkably lower than downloads, indicating a passive use of the platform. On the other platforms, discussions and downloads are considerably less than the number of subscribers, similarly to the activity of our platform. These results confirm the potential but also the limits of digital instruments in the training for specialists, both in headaches and in other disorders.
Headache know-how, headache centers organization ad clinical activity: results from a national survey E. Mampreso Headache Centre, Neurology, AULSS6 Euganea, Padua, Italy; e-mail: edoardo.mampreso@aulss6.veneto.it
Objective: To evaluate the Bstate of the art^of headache know-how between Members of the Italian Society for the Study of Headaches (SISC) and organization in SISC headache centers. Methods: We send a codified email link to an official mailing list of SISC Members, to answer a web-based, anonymized survey; it was possible to complete the survey in different times from 01.09.2014 for 48 days; there were mandatory questions and optional questions; multiple choice answers. Results: Four hundred and fifty-five questionnaires were sent, 188 were answered (41%), among these 155 were assessable (34%); 74 responses from women (47.7%), 81 from men (52.3%), average age 50.3 ±11.3. Most participating regions were: Lazio (22 questionnaires), Sicilia (16), Lombardia (14), Veneto (13); same percentage of participation among those working in university and non-university centers. Sixty percent of responders refers to be experienced with lessons about headaches during the course of studies, mainly with a duration of weeks (67%) and only theoretical (55%); among those who had taken lessons (Beducated^) the same were considered adequate (58%) to acquire competence to dedicate themselves to headaches; among Beducated^the average SISC membership was 9.4 years and average working time 16.4 years, while, among the Buneducated", average SISC membership were 12.4 years and average working time 26.7; 92% of respondents had attended in the last 2 years congresses on headaches; the percentage of doctors dedicated to headaches in the total of the unit is generally less than 30%. About daily clinical activity: 60% use paper schedule and 66% use a semi-structured questionnaire; 56% use ICHD III beta; 86% adopted SISC guidelines; 99% use headache diary which, in 66%, is self-made; off-label prescriptions are "a limit" for 10% of university center doctors and 13% of non-university doctors, a "second choice" for 48% of university and 59% for non-university, "no limit" for 42% of university and 28% for non-university. Conclusions: This survey was appreciated: 41% answered; there was a heterogeneously participation among regions; basic knowhow about headaches is present, brief, but is considered quite formative; we observed a good update about headaches between SISC Members; headache specialists are not so widespread in teams; until today the digital gap is too elevated (only 40% use digital schedule); ICHD-III beta is used in more 50%; 86% of SISC members use Society guidelines; furthermore there's a tendency to off-label prescription (especially in university centers). [2018] [2019] [2020] [2021] aims at providing an innovative organizational model and an advanced technological platform of services for supporting the integrated clinical management of headache patients. One of the main features of the project concerns the integration of patient-centered healthcare pathways, by involving and supporting the same patient in the selfmanagement of the disease. To this end, the BALCMEONE App^is currently under development and testing. Methods: The BALCMEONE App^is based on a state-of-the-art software artefact allowing to realize a suitable environment that envelops and sustains the headache patient for the self-management of the disease. In order to design and develop the system, the main issues concern the definition of a user-friendly interface, which allows an immediate and intuitive interaction with the end-user, and an efficient data collection and communication infrastructure, which guarantees a seamless and interoperable integration with the different healthcare informative systems. The proposed technological approaches exploit the most innovative solutions of the Bman-machine interaction^domain. Results: The BALCMEONE App^supports patients in the management of health conditions, providing the Bheadache diary^, services for the control of the therapy compliance, questionnaires for monitoring the life style and detect the current status of the disease. All the collected data and information are made available, with the appropriate access rights and by assuring the relevant privacy policy, to all the relevant healthcare operators. Conclusions: Following a patient centered perspective, BALCMEONE App^is adaptable (different languages, gender and age tailored), is integrable (electronic health record, different healthcare information systems, medical devices and sensors, environmental sensors), compatible with the most recent technological standard, also enabling participation of patients and relatives in care processes. BALCMEONE App and Platform^jointly provide an effective collaboration tool involving patients and health care professionals.
A decision support system for headache diagnosis based on ICHD-3 R. Costabile Background: Automatic or semi-automatic software tools have proven to be successful at assisting practitioners in the diagnosis of pathologies. The headaches domain is challenging due to the high amount of possible diagnosis and diagnostic criteria. The International Classification of Headache Disorders 3rd edition (ICHD-3), is considered by the World Health Organization as the official classification of headaches. ICHD-3 provides specific diagnostic criteria for diagnosing known headaches. The possible diagnoses are organized in a hierarchical structure that expresses the existing relationships between them. ICHD-3 guidelines are
